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General introduction: Advances in prognosis 
and management of early breast cancer and 




ADVANCES IN PROGNOSIS AND MANAGEMENT OF 
EARLY BREAST CANCER 
 
Breast cancer incidence and mortality 
 
The incidence of breast cancer in The Netherlands is among the highest in the 
world. Breast cancer accounts for 33.6% of all cancers in Dutch women.1 The 
absolute number of breast cancer cases increased from 7,900 in 1989 to 11,200 
in 2000. In the same period the age standardised breast cancer incidence 
increased from 99.9 to 123.1 per 100,000 women (Figure 1). Based on present 
incidence rates, about 1 in every 8-9 women in The Netherlands will develop 
breast cancer.1 Despite this increasing incidence, mortality due to breast cancer 
has slowly, but steadily, decreased from 39.0 per 100,000 women in 1989 to 33.5 
in 2000 (Figure 1.1).1 Between the 1970s and the early 2000s, the 5-year overall 
survival gradually increased from approximately 60% to approximately 80%.2 The 
decrease in mortality has been attributed to the nationwide screening programme, 
which was gradually implemented in The Netherlands between 1989 and 1997.3,4 
However, evolvements in the management of early breast cancer, in particular the 





Till 1980 primary surgical treatment of patients with early breast cancer consisted 
of modified radical mastectomy (MRM). In 1981 breast conserving therapy (BCT) 
was introduced in The Netherlands for patients with tumours ≤ 2 cm in diameter. 
In 1984 the indication for BCT was extended to tumours ≤ 3 cm. The proportion of 
patients receiving BCT gradually increased from 26% in 1984 to 53% in 1991.6,7 
Radiotherapy directed towards the whole breast, with an additional boost dose to  
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Figure 1.1. Annual, age-adjusted breast cancer incidence and mortality per 100.000 women 




























the original tumour site, was administered as part of BCT. Radiotherapy directed 
towards the thoracic wall and regional lymph nodes was given to almost all 
patients until the mid 1980s, but from that time the administration of locoregional 
radiotherapy was restricted to patients with a high risk for locoregional 
recurrence.8 In the IKMN-region indications for locoregional radiotherapy were: 
tumour diameter more than 5 cm, irradical resection (axilla or thoracic wall), fixed 
axillary lymph nodes, more than 3 positive axillary lymph nodes, or a positive 
axillary top node.9 The administration of locoregional radiotherapy in high-risk 
patients has a positive influence on survival. In the 1990s and early 2000s the 
primary management of early breast cancer remained largely unchanged, besides 




Adjuvant systemic therapy 
 
In the 1980s and 1990s adjuvant systemic therapy was advised according to 
regional treatment guidelines. These guidelines recommended adjuvant systemic 
therapy for axillary node-positive (ANP) patients only. Chemotherapy was 
assigned to premenopausal ANP patients, and endocrine therapy to 
postmenopausal ANP patients (Table 1.1).6,9 In premenopausal patients with 
ANP, oestrogen receptor (ER) positive tumours ovariectomy was considered 
equally effective as adjuvant chemotherapy,10 but was generally not 
recommended. In the 1980s the proportion of ANP patients receiving any form of 
adjuvant systemic therapy increased from 49% in 1984 to 82% in 1991. The 
proportion of axillary node-negative (ANN) patients receiving adjuvant systemic 
therapy did not change and was less than 3%.6 Between 1991 and 2000 the use 
of adjuvant systemic therapy remained stable,4,5 but within The Netherlands 
differences in the management of ANN breast cancer grew.11 Therefore, the 
Dutch Society for Medical Oncology organised in 1998 a consensus meeting on 
the adjuvant treatment of ANN breast cancer. Conclusions of this meeting were 
that adjuvant systemic treatment was indicated for all ANP patients, and for ANN  
 
 
Table 1.1. 1996 IKMN-guideline for adjuvant systemic therapy.9  
 





grade HR <36 36-49 50-59 60-69 >=70
0 any any any      
>0 any any any      
 
□ no adjuvant systemic therapy 
■ adjuvant chemotherapy (4 cycles AC) 
■ adjuvant endocrine therapy (tamoxifen for at least 2 years) 
 
HR: hormone receptor; AC: doxorubicin / cyclophosphamide. 
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Table 1.2. 2002 Dutch guideline for adjuvant systemic therapy.13 
 





grade HR <36 36-49 50-59 60-69 >=70
pos      0.1-1.0 any 
neg      
pos      I-II 
neg      
pos      
1.1-3.0 
III 
neg      
pos      
0 
>3.0 any 
neg      
pos      >0 any any 
neg      
 
□ no adjuvant systemic therapy 
■ adjuvant chemotherapy (4 cycles AC or 6 cycles CMF) 
■ adjuvant endocrine therapy (5 years tamoxifen) 
■ adjuvant combination therapy (both modalities) 
 





patients with a tumour diameter more than 3 cm, or with a tumour diameter 
between 1 and 3 cm and a poor histological grade or high mitotic counts.11 The 
consensus was implemented in the multidisciplinary, evidence-based Dutch 
guideline for the treatment of breast cancer published in 2002 (Table 1.2),12,13 and 
produced a 50% increase in the number of patients assigned to adjuvant systemic 
treatment.14 In 2004 the 2002 guideline was revised. Indications for adjuvant 
systemic therapy were further extended (Table 1.3).15 
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Adjuvant endocrine therapy 
 
In the 1980s adjuvant endocrine therapy with tamoxifen was recommended for 
patients with ER positive tumours only. But, between 1986 and 1991 the 
proportion of postmenopausal patients with ANP, ER negative tumours that 
received adjuvant tamoxifen increased from less than 10% to more than 40%,6 a 
trend probably attributable to the results of some trials and meta-analyses 
reported in this period.10,16,17 In line with this trend, the regional guideline from the 
Comprehensive Cancer Centre Middle Netherlands (IKMN), published in 1996, 
recommended tamoxifen for all ANP patients aged 50 years or more.9 However, 
in 1998 the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) 
concluded, based on their meta-analyses performed in1995, that in ER negative 
disease tamoxifen has little effect on recurrence or breast cancer related 
mortality.18 On the other hand, in ER positive disease 5 years of treatment with 
tamoxifen reduces the breast cancer mortality rate by about 31%.19 As a result, 
the 2002 Dutch guideline recommended that adjuvant tamoxifen should be given 
to patients with hormone receptor positive (oestrogen or progesterone) tumours 
only.11-13 In recent years adjuvant treatment with aromatase inhibitors has 
emerged as a new, and probably more effective, option for postmenopausal 
patients with hormone receptor positive tumours.20 In the ATAC trial, a trial 
comparing adjuvant treatment with anastrozole with adjuvant treatment with 
tamoxifen, anastrozole reduced the disease recurrence rate, by about 13%.21 The 
2004 Dutch guideline recommends an aromatase inhibitor after initial therapy with 





In the 1980s and early 1990s the preferred regimen of adjuvant chemotherapy 
comprised 6 cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF).  
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Table 1.3. 2004 Dutch guideline for adjuvant systemic therapy.15 
 





grade HR <36 36-49 50-59 60-69 >=70
I any      
pos      0.0-1.0 II-III 
neg      
pos      I-II 
neg      
pos      
1.1-2.0 
III 
neg      
pos      I 
neg      
pos      
2.1-3.0 
II-III 
neg      
pos      
0 
>3.0 any 
neg      
pos      1-3 any any 
neg      
pos      >3 any any 
neg      
 
□ no adjuvant systemic therapy 
■ adjuvant chemotherapy (5 cycles FEC or FAC, in specific patients 6 cycles TAC) 
■ adjuvant endocrine therapy (premenopausal: 5 years tamoxifen; postmenopausal: tamoxifen for 2-3 
years followed by an aromatase inhibitor for 3-2 years) 
■ adjuvant combination therapy (both modalities) 
 
HR: hormone receptor; FEC: fluorouracil / epirubicin / cyclophosphamide; FAC: fluorouracil / doxorubicin / 




In the 1990s this regimen was gradually replaced by a regimen comprising 4 
cycles of doxorubicin and cyclophosphamide (AC). Although both regimens were 
considered equally effective22 -both regimens reduce the annual breast cancer 
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mortality rate by about 27% among women aged under 50, and 11% among 
those aged 50-6923- AC was recommended instead of CMF, under the impression 
that AC was a lesser burden to the patient.9 In 1998 the EBCTCG reported the 
suggestion that, compared to CMF, anthracycline-containing regimens produced 
somewhat greater effects on recurrence and mortality.23 This suggestion was 
confirmed by their meta-analyses performed in 2000 (reported in 2005).19 
However, the anthracyclin-containing regimens tested were usually given for 
about 6 months, instead of 3 months with regular AC, and in combination with 
other cytotoxic drugs. Fluorouracil, doxorubicin, cyclophosphamide (FAC), and 
fluorouracil, epirubicin, cyclophosphamide (FEC) were the combinations most 
widely studied. Adjuvant treatment with FAC or FEC reduces the breast cancer 
mortality rate by about 38% among women aged under 50, and 20% among 
those aged 50-69.19 The 2004 Dutch guideline for the treatment of breast cancer 
recommends adjuvant chemotherapy with a regimen comprising 5 cycles of FEC 
or FAC, instead of CMF or AC.15 New, even more effective regimens are 
emerging. A recently published trial compared 6 cycles of treatment with either 
docetaxel, doxorubicin, cyclophosphamide (TAC) or FAC in women with axillary 
node positive breast cancer. In this trial treatment with TAC, as compared with 
FAC, resulted in a 28% reduction in the risk of disease recurrence.24 Based on 
this trial, the 2004 Dutch guideline recommends TAC for premenopausal patients 
with ANP breast cancer overexpressing the HER2/neu receptor.15 
 
 
OUTLINE OF THIS THESIS 
 
As shown, in the past decades the management of early breast cancer has 
considerably changed. Adjuvant treatment decision-making has become much 
more complex, and prognostication has gained in importance. All studies in this 
thesis are dealing either with prognostication or with the consequences of a 
change in the management of early breast cancer. 
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Prognostic factors in early breast cancer are defined as measurements available 
at time of surgery that are associated with outcome. Prognostic factors are 
clinically relevant when they are used for treatment decision-making. In the 1980s 
involvement of the axillary lymph nodes was the only prognostic factor considered 
clinically relevant. The National Institutes of Health Consensus Panel on the 
Adjuvant Therapy and Endocrine therapy for Breast Cancer concluded in 1985 
that routine administration of adjuvant systemic therapy in women with 
histological negative axillary lymph nodes could not be recommended.25 But, in 
the late 1980s and early 1990s the administration of adjuvant systemic therapy to 
ANN patients became a mater of debate.26,27 a major conclusion at the St. Gallen 
Conference held in 1988 was that most ANN patients should also be treated with 
some form of adjuvant therapy.28 As a consequence, additional prognostic factors 
were needed to define high-risk ANN patients. For this matter, in 1989 a study 
was started in 5 hospitals located in the Middle-Netherlands. Consecutive patients 
with operable breast cancer were asked to participate in a prospective 
observational study on prognostic factors. The primary goal of this study was to 
evaluate the clinical relevance of a large number of potential prognostic factors. A 
secondary goal was to construct a prognostic index by which adjuvant therapy 
can be either omitted or adjusted to prognosis. This study is presented in Chapter 
2 of this thesis.  
 
In studies on early breast cancer, outcome is usually defined as the time from 
diagnosis or surgery until a particular endpoint. The endpoint can vary, and may 
include death, disease related death, or recurrent disease. However, an explicit 
definition of the endpoint used is provided in less than half of published studies.29 
In Chapter 3 data from the cohort of patients presented in Chapter 1 are used to 
evaluate the effects of various definitions of outcome on estimated outcome 
probability. The presented study specifically focuses on the influences of non-
disease related death and contralateral breast cancer. 
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Hormone receptors are considered weak prognostic factors.30 Three techniques 
for ER and progesterone receptor (PR) determination are commonly used: ligand 
binding assay (LBA), immunocytochemical assay (ICA), and enzyme immuno 
assay (EIA). At least until 1992, LBA has been the preferred and most commonly 
used method.31 But nowadays, most, if not all, hospitals in the Netherlands use 
ICA. The prognostic value of EIA and ICA appear of the same magnitude 
compared with that of LBA.32,33 But, the prognostic value of ICA and EIA has not 
been compared with each other before. In Chapter 4 the prognostic value of ER 
and PR detected both by ICA and EIA is prospectively compared in a subgroup of 
patients from the cohort presented in Chapter 1. 
 
The broad use of adjuvant systemic therapy in ANN breast cancer was introduced 
in the Netherlands after the 1998 consensus meeting. The Dutch guideline for the 
treatment of breast cancer, published in 2002, used tumour size, and histological 
grade or mitotic counts to select ANN patients for adjuvant systemic therapy.12,13 
In Chapter 5 the reproducibility and prognostic value of histological grade and 
mitotic counts is studied specifically in patients with ANN breast cancer. Selected 
is a subgroup of patients from the cohort presented in Chapter 1, that is ANN and 
that did not receive adjuvant systemic therapy. 
 
The major question, however, is not simply how to select patient categories that 
are at high risk for recurrence, but how to select patient categories for which the 
usefulness of adjuvant systemic therapy is high enough to justify its side effects 
and inconvenience. It is complex to predict the benefit of adjuvant systemic for an 
individual woman with early breast cancer. It involves integration of information 
about baseline prognosis, efficacy of various treatment options, and estimates of 
competing risk. In 2001 two computer programs, Adjuvant! and Numeracy, were 
introduced that provide an estimate of the absolute benefit associated with 
various commonly used regimens of adjuvant systemic therapy for the individual 
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woman with early breast cancer.34,35 In Chapter 6 the prognostic and predictive 
estimates made by Adjuvant! and Numeracy are mutually compared using the 
cohort of breast cancer patients presented in Chapter 1. In this chapter Adjuvant! 
is also validated for use in the Dutch setting. Prognosis determined with Adjuvant! 
is compared with the observed 10-year overall and relapse-free survival. In 
addition, the absolute benefit in overall survival from adjuvant systemic therapy as 
predicted by Adjuvant! is compared with the presence or absence of an indication 
for adjuvant systemic therapy according to the Dutch guideline from 2002 and the 
revised guideline from 2004. 
 
For breast cancer patients, the optimal sequence of adjuvant chemotherapy and 
radiotherapy is not clearly defined. In the 1980s and 1990s both modalities were 
given concurrently in the IKMN-region. Theoretically, one can expect the largest 
treatment benefit with this policy.36 However, it has been reported that the 
concurrent administration of the two modalities leads to an increased incidence of 
side effects.37 In the 1990s adjuvant CMF chemotherapy was gradually replaced 
by adjuvant AC chemotherapy. In Chapter 7 of this thesis the acute toxicity of 
radiotherapy alone, radiotherapy concurrent with AC, and radiotherapy concurrent 
with CMF is prospectively compared. 
 
In Chapter 8 the results and conclusions from the studies presented in this thesis 
are summarized and discussed in a broader perspective. Chapter 9 is a 
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Prognostic factors in breast cancer. Results of 
a prospective, multicentre, observational study 
on 463 patients with long-term follow-up. 
 
 






Background: The proper use of prognostic factors in primary breast cancer 
might enable individual tailoring of adjuvant treatment. The primary goal of this 
study was to evaluate the clinical relevance of a large number of prognostic 
markers. The secondary goal was to construct a prognostic index by which 
adjuvant therapy can be either omitted or adjusted to prognosis. 
 
Methods: Between 1989 and 1993, 463 patients with operable, stage I to III 
breast cancer were included in this multicentre, prospective, observational study 
on 22 potential prognostic factors. End-points for outcome analysis were: 
locoregional relapse, disease free interval, disease free survival, overall survival, 
and disease specific survival. The median follow-up period was 124 months. 
 
Results: Tumour size, number of involved axillary lymph nodes, and the 
urokinase plasminogen activator system were the strongest predictors of 
outcome. A prognostic index comprising these variables was able to select a 
large group of patients (30%) with a good prognosis. 
 
Conclusion: The importance of the classical prognostic variables, lymph node 
status and tumour size, was confirmed. The data presented in our study suggest 
that the addition of the urokinase plasminogen activator or its inhibitor type 1 to 





The incidence of breast cancer in women in the Netherlands is among the highest 
in the world and rising. In the period 1989-1998, the number of newly diagnosed 
breast cancers in the Netherlands was approximately 95.000. In the same period 
almost 35.000 patients died from breast cancer, i.e. about 30-40% of patients 
initially diagnosed with breast cancer.1 Adjuvant chemotherapy and endocrine 
therapy have shown to improve survival in patients with breast cancer, but also 
have potentially serious side effects, and are costly. In the late eighties and early 
nineties of the 20th century the presence of axillary lymph node metastases was 
the only prognostic indicator routinely used in the Netherlands to decide whether 
or not adjuvant systemic therapy had to be provided.2 It was thought that in 
patients with axillary node negative (ANN) breast cancer the level of efficacy of 
the available adjuvant therapies was not high enough to outweigh the 
disadvantages. However, since approximately 30% of ANN patients will ultimately 
develop distant metastasis, it was also thought that additional prognostic factors 
could be helpful to identify those ANN patients in whom the benefits of adjuvant 
systemic therapy would outweigh the disadvantages. Prognostic factors could 
also be helpful to identify patients whose prognosis is so poor with conventional 
treatment that more aggressive therapy might be warranted. Combinations of 
prognostic factors might enable an improved prediction of the probability of 
recurrences, hence might be helpful tools to decrease the number of over- and 
under-treated patients.3  
 
The primary goal of the present prospective observational study was to evaluate 
the clinical relevance of a large number of potential prognostic factors in early 
breast cancer. A secondary goal was to select a number of appropriate prognostic 
factors by which primary breast cancer patients can be optimally indexed 
according to prognosis and by which, as a result, the administration of adjuvant 






Between October 1989 and March 1993, consecutive female patients diagnosed 
with operable breast cancer, were asked to participate in an observational study 
on prognostic factors. Patients were recruited in 5 hospitals affiliated with the 
Comprehensive Cancer Centre Middle Netherlands (IKMN). A total of 474 women 
gave their written informed consent, of these 463 (98%) were diagnosed with 
stage I-III disease. The IKMN has a cancer-registry that contains data from all 
newly diagnosed cancer patients treated in one of 11 hospitals located in the 
Middle Netherlands, a region with 1.3 million inhabitants. In the inclusion-period of 
this observational study in total 2243 female patients with stage I to III breast 
cancer were registered in the IKMN-registry. Of these, 2165 (97%) patients were 
actually operated. Patient- and tumour characteristics of the 2165 patients 
included in the IKMN-registry and the subset of those included in this registration 




The clinical relevance as prognostic variable of the following patient-, tumour-, 
and treatment characteristics was evaluated: age (≤50, 51-60, 61-70, >70 year), 
menopausal status (pre-, postmenopausal), tumour lateralisation (left, right), 
tumour location in the breast (central, medial, lateral, overlapping), histological 
type (ductal, lobular, other or not otherwise specified), tumour size (0.1-1.0, 1.1-
2.0, 2.1-3.0, >3.0 cm), tumour free margins (present, absent), in-situ component 
(none, marginal, extensive), in-situ component free margins (present, absent), 
number of axillary lymph nodes resected (0-6, 7-12, >12), number (0, 1-3, >3 
positive nodes) and level (negative, positive top-node) of axillary lymph node 
metastases. 
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Moreover, the prognostic value of the following variables was studied: oestrogen- 
and progesterone receptor value using either enzyme immuno assay (≤15, >15 
fmol/mg protein) or immunohistochemistry (≤10%, >10% positive staining), 
histological grade according to the revised Bloom-Richardson scoring system, 
mitotic counts (≤12, >12 mitoses/2mm2), DNA-index (diploid, aneuploid), S-phase 
fraction (≤ median, > median value), and cathepsin-D, pS2, urokinase 
plasminogen activator (UPA) and its inhibitor type 1 (PAI-1) (all ≤ median, > 
median value). Pathological data were obtained from local pathology reports. 
DNA-index and S-phase fraction were determined with dual parameter flow 
cytometry at the University Medical Centre Utrecht. Biochemical tests (hormone 
receptors, Cathepsin D, pS2, UPA, and PAI-1) were performed at the department 
of endocrinology of the University Medical Centre Utrecht. Of some prognostic 
markers - histological grade (62%), mitotic counts (87%), S-phase fraction (86%), 
Cathepsin D (58%), pS2 (52%), UPA (46%), and PAI-1 (46%) - data were 




End-points for outcome analysis were time from primary surgery until death 
(overall survival, OS), time from primary surgery until death related to breast 
cancer (disease specific survival, DSS), time from primary surgery until 
recurrence (disease free interval, DFI), time from primary surgery until death or 
recurrence whichever came first (disease free survival, DFS), and time from 
primary surgery until locoregional recurrence (locoregional recurrence rate, 
LRRR). We defined locoregional recurrence as either recurrent disease in the 
skin or soft tissue of the chest wall, the ipsilateral breast and lymph nodes in the 
ipsilateral axilla, the infraclavicular fossa or the internal mammary chain. Death 
was classified as related to breast cancer when death was probably caused by 
breast cancer in the presence of distant metastases. Recurrence was defined as 
either locoregional recurrence or distant metastasis whichever came first. 
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Table 2.1. Patient and tumour characteristics. Comparison between study-population and patients 








Age (years)    
≤ 50 31 35 * 
51 – 70 43 44  
> 70 26 21  
Histology    
Ductal 74 68 * 
Lobular 10 11  
Other 13 18  
Adenocarcinoma n.o.s. 3 3  
Pathological T-stage    
T1 57 61 * 
T2 32 33  
T3 or T4 8 6  
Unknown 4 0  
Pathological N-stage    
N0 61 59  
N1, N2 or N3 36 39  
Unknown 2 2  
Postoperative treatment    
Radiation therapy 62 65  
Chemotherapy  13 16  
Hormonal therapy 26 31 * 
 






Median follow-up was determined with the inverse Kaplan-Meier method.4 10-year 
survival and event rates were determined using timetables. For all evaluated 
prognostic factors differences in LRRR, DFI, DFS, OS, and DSS were compared 
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using univariate Cox proportional hazard regression analyses. Selected 
prognostic factors were further analysed using multivariate Cox proportional 





Patient-, tumour-, and treatment characteristics 
 
Overall, the study-population was a representative sample of the IKMN-registry 
(Table 2.1). However, study-patients were slightly younger, with a median age of 
58 years versus 60 years in the registry-population. The histological classification 
differed, with less infiltrating ductal carcinomas in the study-population. In the 
registry-population the T-stage was unknown in 4% op patients, compared with 
0% in the study-population. And, more study-patients were treated with adjuvant 
tamoxifen. The studied population was not different from the IKMN-registered 
population considering axillary nodal status, and use of chemotherapy or 
radiotherapy.  
The 463 tumours included in this study were equally divided between the left and 
right breast, 41% of tumours were located in the lateral upper quadrant of the 
breast. In-situ carcinoma was found in 52% of patients, in 21% the in-situ 
component was extensive. The presence or absence of axillary lymph node 
metastases was investigated in 98% of patients. A median number of 13 nodes 
were investigated (range 0-31), in 69% of patients >10 axillary lymph nodes were 
investigated. 39% of tumours were axillary node positive (ANP), 59% were 
axillary node negative, and from 2% of tumours the axillary nodal status was 
unknown. In 39% of ANP patients 1 lymph node was involved; 2-3, 4-9, and >9 
lymph nodes were involved in 29%, 15% and 17% of ANP patients, respectively. 
Positive axillary lymph nodes were found in 30%, 49%, and 73% of T1, T2 and  
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Figure 2.1. Relative proportion of patients treated with modified radical mastectomy [□], breast 



















T3-4 tumours respectively. Axillary top-nodes were involved in 31% of ANP 
patients. Primary surgical treatment consisted of breast conserving therapy (BCT) 
in 57% of patients, or modified radical mastectomy (MRM) in 41% of patients. 
Older patients were more often treated with MRM (Figure 2.1). Larger tumours, 
when compared with smaller ones, were also more often treated with MRM: 69%, 
57% and 29% of T3, T2 and T1 tumours respectively. At initial surgery the 
infiltrative component was not radically resected in 10% of patients, the in-situ 
component was not radically resected in 6% of patients. Radiotherapy was 
administered to 65% of patients. After breast conserving surgery 99.6% of 
patients received radiotherapy. After MRM radiotherapy was administered to 19% 
of patients. Adjuvant systemic therapy was administered to 44% of patients; to 
13% of axillary node negative patients and to 91% of axillary node positive 
patients. Adjuvant chemotherapy, either doxorubicin / cyclophosphamide (AC) or  
 25
Figure 2.2. Percentage of patients treated with chemotherapy [□] and hormonal therapy [■] 



















cyclophosphamide / methotrexate / fluorouracil (CMF), was administered 
exclusively to patients less than 60 years of age, adjuvant hormonal therapy 
predominantly to older patients (Figure 2.2). Hormone receptors were determined 
in 95% of patients. 76% of tumours were oestrogen receptor positive, 66% of 
tumours were progesterone receptor positive. 61% of tumours were both 
oestrogen- and progesterone receptor positive. Hormone receptor determination 
did not influence the number of patients treated with adjuvant hormonal therapy. 
Adjuvant hormonal therapy was administered to 28% of oestrogen-receptor 
negative patients and 31% of oestrogen-receptor positive patients. Although we 
have no data on duration of endocrine therapy, we expect most patients were 
treated with tamoxifen for 2 to 5 years. 
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Table 2.2. Association between evaluated prognostic variables and LRRR, DFI, DFS, OS, and DSS 
in univariate Cox-regression analyses. 
 10-year rate (%) 
 
Number of   
patients LRRR DFI DFS OS DSS 
All patients 463 12  69  59  67  78  
Age        
≤ 50 year 163 14  62  60 † 70 ‡ 73  
51-60 year 100 10  72  69  75  79  
61-70 year 102 8  74  62  72  87  
> 70 year 98 13  73  39  44  79  
Tumour size        
0.1 – 1.0 cm 79 8  85 ‡ 70 ‡ 76 ‡ 92 ‡ 
1.1 – 2.0 cm 204 11  72  64  74  83  
2.1 – 3.0 cm 104 10  67  55  57  68  
> 3.0 cm 76 17  52  38  49  64  
Axillary lymph nodes        
0 tumour positive 275 11  77 ‡ 67 ‡ 75 ‡ 86 ‡ 
1 – 3 tumour positive 120 14  65  54  61  72  
> 3 tumour positive 61 8  45  36  43  55  
Unknown 7       
Axillary top-node        
Tumour negative 393 12  74 ‡ 63 ‡ 71 ‡ 81 ‡ 
Tumour positive 57 9  44  34  43  58  
Unknown 13       
Histological grade        
I 95 9  82 * 70 * 82 † 95 † 
II 163 12  68  57  64  75  
III 74 13  67  56  61  74  
Unknown 131       
Mitotic counts        
≤ 12 mitoses / 2 mm2 266 10 * 72 * 63 * 73 † 83 ‡ 
> 12 mitoses / 2 mm2 139 15  63  54  60  69  
Unknown 58       
Cathepsin D        
≤ median value 138 13  73  63 * 72 * 81  
> median value 132 9  67  53  60  75  
Unknown 193       
UPA        
≤ median value 108 12  75 * 69 † 78 † 84 * 
> median value 107 15  60  47  56  70  
Unknown 248       
PAI-1        
≤ median value 108 11  77 † 71 ‡ 81 ‡ 88 † 
> median value 107 16  58  45  53  66  
Unknown 248       
 
* P<0.05, † p<0.01, ‡ p<0.001. Abbreviations: LRRR: locoregional relapse rate; DFI: disease free interval; DFS: 
disease free survival; OS: overall survival; DSS: disease specific survival; UPA: urokinase plasminogen activator; 




Patients who survived were followed until December 2002. The median follow-up 
period was 10.3 years. During follow-up 151 patients died, 92 deaths were related 
to breast cancer, the other 59 patients died from causes unrelated to breast 
cancer. The 10-year OS was 67%, the 10-year DSS 78%. Distant metastases 
were diagnosed in 111 patients (10-year event rate 25%). In 49% of patients 
distant metastases were primarily diagnosed in the skeletal system. Loco-regional 
recurrence occurred 47 patients (10-year event rate 12%), and in 30 patients 
breast cancer was diagnosed in the contralateral breast. A second primary 
malignancy was diagnosed in 27 patients. The 10-year DFI was 69% (134 
events), the 10-year DFS 59% (191 events). 
 
Analysis of potential prognostic markers 
 
In univariate analysis the following variables were not significantly associated with 
any of the survival end-points: menopausal status, tumour lateralisation, tumour 
location in the breast, histological type, tumour free margins, in-situ component, 
in-situ component free margins, number of axillary lymph nodes resected, 
oestrogen- and progesterone receptor value, DNA-index, S-phase fraction, and 
pS2. These markers were not further investigated. The univariate association 
between the other prognostic markers and the studied outcome end-points is 
provided in Table 2.2. A positive top-node was found in 13%, 61% and 84% of 
patients with 1-3, 4-9 and >9 positive axillary lymph nodes, respectively. After 
stratification for the number of axillary lymph node metastases no significant 
association between the presence of tumour cells in the highest axillary lymph 
node and DFI (p=0.39), DFS (p=0.18), OS (p=0.35) or DSS (p=0.99) remained. 
The prognostic value of the level of the lymph node metastasis was not further 
investigated. Age and Cathepsin D were associated with DFS and OS only. Age 
was primarily associated with non-breast cancer related mortality (p<0.001). The  
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Figure 2.3. Locoregional relapse rate according to mitotic counts and treatment with radiotherapy. 
A: high mitotic counts, no radiotherapy; B: low mitotic counts, radiotherapy; C: high mitotic counts, 
radiotherapy; D: low mitotic counts, no radiotherapy. 
 
 







A 96 91 86 73 63 36
B 171 166 152 145 115 67
C 47 37 31 26 17 13























association between Cathepsin D and DFS (p=0.05) and OS (p=0.03) was not 
very strong. In univariate analysis BCT, compared with MRM, was associated 
with a significant better DFI (p=0.02), DFS (p=0.002), OS (p=0.001) and DSS 
(p=0.02). After stratification for tumour size no significant association with DFI 
(p=0.40), DFS (p=0.10), OS (p=0.06) or DSS (p=0.83) remained. The prognostic 
value of type of primary surgical therapy was not further investigated. The 
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administration of radiotherapy was associated with a significant better DFS and 
OS. After stratification for age no significant association with DFS (p=0.26) or OS 
(p=0.40) remained. In univariate analysis both the administration of radiotherapy 
and low mitotic counts were associated with a lower LRRR (p<0.05). In 
multivariate analysis, only patients with high mitotic counts, not treated with 
radiotherapy had an elevated risk of locoregional recurrence (Hazard ratio 5.0, 
95% C.I. 2.0 – 12.6) (Figure 2.3). Adjuvant systemic therapy was primarily 
administered to ANP patients, and was associated with a significant (p<0.01) 
worse DFI, DFS, OS and DSS. After stratification for the number of axillary lymph 
node metastases no significant association with DFI (p=0.35), DFS (p=0.86), OS 
(p=0.29) or DSS (p=0.91) remained. 
 
Construction of a prognostic index 
 
In univariate analysis tumour size and the number of positive axillary lymph nodes 
were the strongest predictors of DFI, DFS, OS and DSS (p<0.001), and were 
determined in more than 98% of patients. Age over 70 years was strongly 
associated with a worse DFS and OS (p<0.001). Histological grade, mitotic 
counts, UPA, and PAI-1 were also significantly associated with DFI, DFS, OS, 
and DSS, but were hindered with higher numbers of missing data. The prognostic 
value of tumour size, number of positive axillary lymph nodes, and age combined 
with the administration of adjuvant therapy was investigated further in a 
multivariate Cox regression model (Table 2.3). They proved independent 
predictors of DFI, DFS, OS and DSS, and were subsequently used to construct 3 
risk groups: low-risk (tumours ≤ 1.0 cm in diameter, and ANN), high-risk (tumours 
> 3.0 cm in diameter, or >3 axillary lymph nodes involved) and intermediate-risk 
(not low- or high-risk). 9% of patients in the low-risk group, compared with 69% of 
patients in the high-risk group were treated with adjuvant therapy. Patients in the 
low-risk group had a significant better prognosis compared with patients in the 
high-risk group (p<0.001) (Table 2.4). In the low-risk group prognosis was good  
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Table 2.3. Association between age, tumour size, number of axillary lymph nodes and adjuvant 
therapy and age, risk group and adjuvant therapy, and LRRR, DFI, DFS, OS, and DSS in 
multivariate Cox-regression analyses. Significant hazard ratios (p<0.05) are bold. 
 
 Hazard ratio (95% confidence interval) 
 DFI DFS OS DSS 
     
Age     
≤ 70 year 1.0 1.0 1.0 1.0 
> 70 year 0.71 (0.44-1.1) 1.6 (1.2-2.3) 2.2 (1.5-3.1) 0.92 (0.53-1.6)
Tumour size     
0.1-1.0 cm 1.0 1.0 1.0 1.0 
1.1-2.0 cm 1.8 (0.93-3.5) 1.3 (0.80-2.1) 1.1 (0.63-1.9) 2.1 (0.83-5.5) 
2.1-3.0 cm 2.3 (1.2-4.6) 1.6 (0.96-2.7) 1.8 (1.0-3.2) 4.1 (1.6-10.9) 
> 3.0 cm 3.2 (1.6-6.5) 2.0 (1.2-3.4) 1.7 (0.96-3.2) 4.0 (1.5-10.9) 
Axillary lymph nodes     
0 tumour positive 1.0 1.0 1.0 1.0 
1-3 tumour positive 1.8 (0.99-3.3) 1.4 (0.85-2.3) 1.4 (0.78-2.4) 2.0 (0.97-4.2) 
> 3 tumour positive 3.1 (1.6-5.9) 2.2 (1.3-3.9) 2.2 (1.2-4.1) 3.5 (1.6-7.5) 
Adjuvant systemic therapy     
No 1.0 1.0 1.0 1.0 
Yes 0.73 (0.41-1.3) 0.94(0.59-1.5) 1.1 (0.67-1.9) 0.88 (0.44-1.8)
     
     
Age     
≤ 70 year 1.0 1.0 1.0 1.0 
> 70 year 0.66 (0.41-1.1) 1.6 (1.2-2.2) 2.2 (1.5-3.0) 0.83 (0.48-1.4)
Risk group     
Low or interm. / low PAI-1 1.0 1.0 1.0 1.0 
Interm. / undetermined PAI-
1 
1.8 (1.1-3.2) 1.7 (1.1-2.6) 2.0 (1.2-3.4) 3.6 (1.5-8.3) 
High or interm. / high PAI-1 3.7 (2.2-6.2) 2.8 (1.8-4.2) 3.1 (1.8-5.2) 6.7 (3.0-15.1) 
Adjuvant systemic therapy     
No 1.0 1.0 1.0 1.0 
Yes 1.1 (0.79-1.6) 1.2 (0.87-1.6) 1.4 (0.96-1.9) 1.4 (0.91-2.2) 
     
 
Abbreviations: DFI: disease free interval; DFS: disease free survival; OS: overall survival; DSS: disease specific 




enough to omit adjuvant systemic therapy, whereas patients in the high-risk group 
were clearly indicated to receive adjuvant systemic therapy. However, most 
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patients (60%) were classified intermediate-risk. Therefore, the prognostic 
significance of age, histological grade, mitotic counts, Cathepsin D, UPA and PAI-
1 was further investigated in the 277 patients with an intermediate risk (Table 
2.4). UPA and PAI-1 were the strongest predictors of DFI, DFS, OS, and DSS in 
the subgroup of patients with an intermediate risk based on tumour size and 
number of involved axillary lymph nodes (p<0.01). The DFI and DSS of 
intermediate-risk patients with a low UPA or PAI-1 were equal to the DFI and DSS 
of low-risk patients, whereas the DFI and DSS of intermediate-risk patients with a 
high UPA or PAI-1 were almost equal to the DFI and DSS of high-risk patients. 
UPA and PAI-1 were not determined in 145 (52%) intermediate-risk patients. The 
DFI and DSS of these patients were 74% and 80% respectively, comparable to 
the DFI (73%) and DSS (81%) of all 277 patients in the intermediate risk group. 
The intermediate-risk group was split up. Patients with an intermediate risk and a 
low PAI-1 value were added to the low-risk group. Patients with an intermediate 
risk and a high PAI-1 value were added to the high-risk group. Patients with an 
intermediate risk whose PAI-1 value was not determined remained in the 
intermediate-risk group. With these risk groups a large group of patients with low 
risk (10-year DSS 95%) could be distinguished from patients with high risk (10-
year DSS 64%) (Figure 2.4). In multivariate analysis the prognostic value of these 
risk groups was independent of age and treatment with adjuvant therapy (Table 





The 463 patients included in this study are a representative sample of patients 
diagnosed with stage I-III operable breast cancer in the Middle Netherlands. 
Patient- and tumour characteristics are in accordance with those reported in 
literature.2,5,6 Treatment figures are also in accordance with the views in the 
inclusion period of this study. Surgical therapy was breast sparing in 57% of  
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Table 2.4. Association between risk group and LRRR, DFI, DFS, OS, and DSS, and between 
prognostic variables and LRRR, DFI, DFS, OS, and DSS for intermediate risk patients only. 
 




patients DFI DFS OS DSS 
Risk group      
Low (≤1.0 cm and ANN) 68 86 ‡ 72 ‡ 79 ‡ 95 ‡ 
Intermediate (not low/high risk) 277 73  64  71  81  
High (>3.0 cm or N4+) 118 51  38  49  63  
      
      
Analyses of intermediate risk patients only (n=277) 
      
Age      
≤ 70 year 223 73  67 † 74 † 80  
> 70 year 54 75  49  57  84  
Histological grade       
I 59 83  73  84 * 94 * 
II 104 71  64  69  76  
III 46 70  57  65  77  
Unknown 68      
Mitotic counts       
≤ 12 mitoses / 2 mm2 167 74  66  75  82  
> 12 mitoses / 2 mm2 85 71  61  66  76  
Unknown 25      
Cathepsin D       
≤ median value 86 77  69  79 * 87 * 
> median value 78 71  62  67  76  
Unknown 113      
UPA       
≤ median value 62 86 † 81 † 89 † 94 † 
> median value 70 60  52  60  68  
Unknown 145      
PAI-1       
≤ median value 68 85 † 81 ‡ 90 ‡ 95 † 
> median value 64 59  49  57  67  
Unknown 145      
 
* P<0.05, † p<0.01, ‡ p<0.001. Abbreviations: DFI: disease free interval; DFS: disease free survival; OS: overall 
survival; DSS: disease specific survival; ANN: axillary node negative; N4+: 4 or more axillary lymph nodes tumour 





Figure 2.4. 10-year disease specific survival according to risk group. 
 












Low risk (≤1.0 cm. and ANN), or intermediate risk and low PAI-1
Intermediate risk and undetermined PAI-1
























A 136 135 127 123 105 66
B 145 138 130 113 94 54





patients. Mastectomy was conducted particularly in older patients and in those 
with larger tumours. During the inclusion period of this study the benefit of 
adjuvant systemic therapy to ANN patients was a matter debate,7,8 but in the 
Netherlands not routinely administered. A population-based study on the 
treatment of early breast cancer in the Southeast Netherlands between 1984 and 
1991 reported that less than 3% of ANN patients received any form of adjuvant 
systemic therapy.2 In the same study the proportion of ANP patients receiving any 
form of adjuvant systemic therapy increased between 1984 and 1991 from 49% to 
 34
82%.2 In the present study adjuvant systemic therapy was administered to 13% of 
ANN patients, and 91% of ANP patients. Adjuvant hormonal therapy was 
administered equally to oestrogen-receptor negative and positive patients, 
probably because adjuvant tamoxifen was thought to have at least some effect in 
oestrogen-receptor negative patients.9,10 Under the above outlined regimen 10-
year survival data were comparable to, or even slightly better than, those reported 
in literature.6 The 10-year overall survival rates for patients with 0, 1-3 and ≥3 
positive axillary lymph nodes were 75% (expected 65-80%), 61% (expected 38-
63%), and 43% (expected 13-27%) respectively. 
 
The primary goal of this prospective study was to evaluate the clinical significance 
of a large number of potential prognostic markers in primary breast cancer. After 
median 10 years follow-up prognostic value for locoregional recurrence was found 
for mitotic counts and the administration of radiotherapy. Patients with high mitotic 
counts, not treated with radiotherapy had an elevated risk of locoregional 
recurrence. As a after breast conserving surgery 99.6% of patients were treated 
with radiotherapy, the patients at risk for locoregional recurrence were those with 
high mitotic counts, treated with MRM, and not treated with radiotherapy. 
Contemporary data on the post mastectomy LRRR and prognostic variables are 
sparse. Recently, Truong et al. reported that poor histological grade was 
associated with a high LRRR in patients with ANN breast cancer less than 5 cm in 
diameter, treated with mastectomy, but not with radiotherapy.11 These results 
warrant further studies after the association between mitotic counts and 
locoregional recurrence after MRM. 
 
After median 10 years follow-up prognostic value for disease recurrence or 
survival was found for age, number and level of positive axillary lymph nodes, 
tumour size, histological grade, mitotic counts, cathepsin D, UPA and PAI-1. In 
the last decades others have published data on the prognostic value of these, and 
many other markers. The results of these studies have been summarised in a 
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number of reviews and treatment guidelines.12-16 But, the major prognostic 
markers that are used in clinical practice still are number of positive axillary lymph 
nodes and tumour size. Exactly these were the strongest prognosticators in the 
present study, and they were used to create 3 risk groups. Subsequently, UPA 
and PAI-1 were able to split-up the intermediate prognosis group in half. Patients 
with a low PAI-1 value had a prognosis equal to low-risk patients, whereas 
patients with a high PAI-1 value had a prognosis equal to high-risk patients. 
Unfortunately PAI-1 was determined in only 48% of patients. Despite this, we 
created, with the use of tumour size, axillary lymph node status and PAI-1, a 
subgroup of 136 (29%) patients with a 10-year DSS of 95% and a 10-year DFI of 
85%. These results are promising, but need validation in an independent cohort of 
patients. 
 
Consensus guidelines, such as the NIH-guideline, the St. Gallen guideline and 
the Dutch CBO-guideline, use sets of prognostic markers to select patients with 
good, intermediate and poor prognosis.12,13,17 But, none of these guidelines uses 
UPA and/or PAI-1. The major drawback for broad use in clinical practise of UPA 
and PAI-1 is a lack in standardization with respect to immunoassays used, 
methods of tumour extraction and protein determination. However, the prognostic 
value of UPA and PAI-1 has already been shown both in a large prospective 
clinical trial,18 and a pooled analysis of 18 datasets including 8377 patients.19 In 
these studies, high levels of UPA and PAI-1 were the strongest predictors of pour 
disease-free and overall survival, apart from lymph node status. The data 
presented here confirm the prognostic impact of UPA and PAI-1, and suggest that 
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Background: A wide variation of definitions of recurrent disease and survival 
are used in the analyses of outcome of patients with early breast cancer. Explicit 
definitions with details both on endpoints and censoring are provided in less than 
half of published studies. 
 
Methods: We evaluated the effects of various definitions of survival and 
recurrent disease on estimated outcome in a cohort of 463 patients with primary 
breast cancer. Outcome estimates were determined both by the Kaplan-Meier 
method and by a competing risk method. 
 
Results: The in- or exclusion of contralateral breast cancer or non-disease 
related death in the definition of recurrent disease or survival strongly affected 
estimated outcome probability. The magnitude was dependent on patient-, 
tumour-, and treatment characteristics. Minor differences were observed between 
estimated outcome determined by the Kaplan-Meier method and the competing 
risk method. 
 
Conclusions: Insight in the contribution of non-disease related death or 
contralateral breast cancer to estimated recurrent disease rate or overall death 






In studies on early breast cancer, outcome is usually defined as the time from 
diagnosis or surgery until a particular event of interest (endpoint). The event of 
interest can vary and may include death (overall survival), disease related death 
(disease specific survival), or recurrent disease (disease free survival). 
 
Altman et al. systematically reviewed the appropriateness of the application and 
presentation of survival analysis in clinical oncology journals.1 They found that 
among papers specifically dealing with death as an end-point, only 47% explicitly 
described this end-point as either any death or only cancer-related death. In as 
much as 61% of papers that studied time to progressive disease the handling of 
non-cancer related mortality was not clearly defined. 
 
In studies on patients with early breast cancer a wide variation of definitions of 
disease free survival is used. These definitions always include local recurrence, 
regional recurrence, and distant metastasis, but sometimes also include non-
disease related death, contralateral breast cancer and in some cases second 
primary cancer. For example, the 1998 overview of randomised trials on adjuvant 
therapy includes contralateral breast cancer in the analysis of disease recurrence, 
but does not include non-disease related death.2 The Intergroup includes non-
disease related death, but contralateral breast cancer only when it occurs 
concurrently with a locoregional or distant relapse.3 In the original reports of the 
NSABP B14 and B20 trials both non-disease related death, contralateral breast 
cancer, and second primary cancer were included as events in the definition of 
disease free survival.4,5 In a recent report with long-term findings from these trials 
the definition of recurrence free survival was restricted to local or regional 
recurrence, or distant metastasis.6  
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Despite these different definitions, many papers on breast cancer survival do not 
provide an explicit definition of recurrent disease. Mirza et al. wrote a review on 
prognostic factors in node-negative breast cancer.7 In the methods section of their 
report they stated that only papers in which overall or disease free survival were 
specified were included in their review. Sixty-three papers from their reference list 
dealt with survival analysis in primary breast cancer. We reviewed the definitions 
of recurrent disease used in these 63 papers. In only 21 out of 47 papers that 
studied time to recurrent disease the definition of recurrent disease explicitly 
described the handling of non-cancer related mortality. Intercurrent deaths were 
censored in 14 papers and counted as events in 7 papers. Eight papers explicitly 
described the handling of contralateral breast cancer. Contralateral breast cancer 
was censored in 1 and considered as event in 7 papers. The handling of second 
primary cancer was described in 7 papers. Second primary cancer was censored 
in 2 and counted as event in 5 papers. 
 
In most papers the survival probability is estimated with the Kaplan-Meier method 
from observed survival times, censored or uncensored.8 Censoring may arise due 
to end of follow-up, loss to follow-up, but also due to a competing event that 
makes further follow-up impossible. The Kaplan-Meier method requires non-
informative censoring, which means that those individuals who are censored 
should be as likely to have the subsequent event of interest as those who remain 
in the study. In particular competing events might cause informative censoring. 
For this reason others have propagated an approach that accounts for informative 
censoring in survival analyses in the presence of competing events.9,10,11 
 
In the present study we used data from a cohort of 463 patients with primary 
breast cancer to evaluate the effects of various definitions of survival and relapse 
on estimated survival probability. We specifically focused on the influences of 
non-disease related death and contralateral breast cancer. A second goal was to 
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evaluate whether differences could be assessed in estimated outcome 




Table 3.1. Patient-, tumour-, and treatment characteristics 
 




≤ 50 year 142 (31) 
51-70 year 213 (46) 
>70 year 108 (23) 
 
Primary surgical therapy 
Breast conserving therapy 266 (57) 
Modified radical mastectomy 190 (41) 
Other 7 (2) 
 
Adjuvant systemic therapy 
Hormonal therapy 142 (31) 
Chemotherapy 72 (16) 
 
Histology 
Ductal 290 (63) 
Other 173 (37) 
 
Tumour size 
≤ 20 mm 272 (59) 
> 20 mm 191 (41) 
 
Axillary lymph nodes 
Negative 278 (60) 




MATERIAL AND METHODS 
 
Between October 1989 and March 1993 463 patients diagnosed with operable, 
stage I to III breast cancer agreed to participate in a prospective registration study 
on prognostic factors. We obtained written informed consent from all patients. 
Treatment was given according to the guidelines of the Comprehensive Cancer 
Centre Middle Netherlands. Patient-, tumour- and treatment characteristics are 
shown in Table 3.1. We assessed follow-up data until December 2002. 
 
The events that were used to determine the different definitions of outcome were 
local- and regional recurrent disease, contralateral breast cancer, distant 
metastasis, disease related death and non-disease related death. In the various 
analyses these events were either ignored, considered as event of interest or as 
competing event (censored), depending on the definition of outcome. Definitions 
of overall survival, diseases specific survival, disease free interval, and disease 
free survival are given in Table 3.2. We defined local recurrent disease as either 
recurrence in the skin or soft tissue of the chest wall or in the ipsilateral breast. 
Regional recurrent disease confined recurrence in the lymph nodes in the 
ipsilateral axilla, the infraclavicular fossa or the internal mammary chain. 
Contralateral breast cancer included invasive breast cancer lesions in the 
contralateral breast regardless of histological type, lymph node involvement, and 
time interval from initial therapy or from subsequent recurrent disease. Breast 
cancer lesions at any other site, including the ipsilateral supraclavicular lymph 
nodes, were classified as distant metastases. We classified death as disease 
related when death was probably caused by breast cancer in the presence of 
distant metastases. Otherwise we classified death as non-disease related.  
 
Survival probabilities were determined both by Kaplan-Meier estimates,8 and 
cumulative incidence competing risk analyses. As outlined by others, the 
competing risk analyses were determined in a two-step process.9,10 First we  
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Table 3.2. Definitions of outcome. 
 
  




Time from surgery until death related to breast cancer. 
Death not related to breast cancer is censored 
(Kaplan-Meier analysis) or treated as competing event 
(competing risk analysis). 
 
Disease free interval Time from surgery until recurrent disease*.  
Death not related to breast cancer is censored 
(Kaplan-Meier analysis) or treated as competing event 
(competing risk analysis). 
 
Disease free survival Time from surgery until recurrent disease* or death 
from any cause. 
 
* In the definition of recurrent disease local recurrence, regional recurrence, and 
distant metastasis are considered events; contralateral breast cancer is ignored, 
treated as event or censored (Kaplan-Meier analysis) / treated as competing 




determined outcome estimates with the Kaplan-Meier method considering both 
the events of interest and the competing risk events as 'events'. In the second 
step, we calculated the conditional probabilities of experiencing the event of 
interest. With these probabilities we estimated the cumulative incidences in the 





During median 10.0 years of follow-up 149 patients died. 91 deaths were related 
to breast cancer, and the other 58 patients died from causes unrelated to breast 
cancer. Local recurrences were diagnosed in 28 patients, regional recurrences in 
24. Distant metastases occurred in 111 patients, and in 30 patients breast cancer 
was diagnosed in the contralateral breast. 
 
 
Table 3.3. Estimated 10-year survival rate according to definition of survival determined both by 
Kaplan-Meier method and the competing risk analysis.  
 
Survival definition 10-year survival rate (%) 







 KM CR KM CR KM CR 
       
Overall survival 68.0 68.0 75.8 75.8 58.6 58.6 
Disease specific 
survival 79.3 80.6 85.3 86.2 71.9 73.7 
       
Disease free survival       
contralateral ignored 59.3 59.3 65.8 65.8 51.2 51.2 
contralateral censored 58.6 59.4 64.9 66.0 51.1 51.6 
contralateral event 55.5 55.5 59.9 59.9 50.2 50.2 
       
Disease free interval       
contralateral ignored 69.4 70.9 74.6 75.8 63.0 64.9 
contralateral censored 68.9 70.9 73.9 75.9 63.2 65.4 
contralateral event 64.8 66.5 67.6 69.2 61.3 63.4 
 
KM: Kaplan-Meier method; CR: competing risk analysis. 
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Estimated with the Kaplan-Meier method, after 10 years of follow-up 68% of 
patients were still alive (overall survival). If no one had died from causes other 
than breast cancer, 79% of patients would have been alive (disease-specific 
survival) (Table 3.3). The estimated 10-year risk of recurrent disease varied 
between 31% and 44% depending only on the definition of relapse. After 10 years 
of follow-up 56% to 59% of patients were still alive and free of recurrent disease 
(disease free survival), but if no one had died in the interim period 65% to 69% of 
patients would have been free of recurrent disease (disease free interval) (Table 
3.3). Compared with the competing risk approach, the Kaplan-Meier method 
slightly underestimated 10-year survival rates when one or more competing 
events were censored instead of ignored. The largest difference (2.0 percent-
point) was found when both non-disease related death and contralateral breast 
cancer were censored (Table 3.3). 
 
Non-disease related death 
 
The difference in estimated survival probability between overall survival and 
disease related survival, and between disease free survival and disease free 
interval is by definition caused by the handling of non-disease related death. As 
older age is associated with a higher probability of non-disease related death, we 
evaluated the effect of patient’s age on estimated survival probability using the 
various definitions of survival. As shown in table 4, patients aged more than 70 
years were at risk for dying from a cause unrelated to breast cancer, whereas 
patients aged 50 years or less seldom died from a cause unrelated to breast 
cancer. As a consequence, in the younger subgroup 10-year overall survival was 
almost equal to 10-year disease specific survival. Whereas in the elderly, 
estimated 10-year disease specific survival was more than 30 percent point better 
than estimated 10-year overall survival (Figure 3.1). In the younger subgroups 
differences between Kaplan-Meier and competing risk estimates were limited (≤ 
1%). In the elderly estimations of 10-year disease specific survival were 82.2%  
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Figure 3.1. Influence of survival definitions on estimated outcome probability in breast cancer 
patients 50 years or less of age (A), and over 70 years of age (B). Both by Kaplan-Meier method 
(solid line) and competing risk analysis (dotted line). 
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DSS: disease specific survival; OS: overall survival; DFI: disease free interval; DFS: disease free survival. 
Contralateral breast cancer was ignored in the definition of relapse. 
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and 84.9% with Kaplan-Meier and competing risk analyses, respectively. 
Estimations of 10-year disease free interval were 73.6% and 77.6% respectively 
for two statistical methods. 
 
 
Table 3.4. Estimated 10-year event rate according to age at diagnosis determined both by Kaplan-
Meier method and competing risk analysis.  
 
Event 10-year event rate (%) 
 ≤ 50 yr  51-70 yr  > 70 yr 
 KM CR  KM CR  KM CR 
         
Overall death 31.1 31.1  23.5 23.5  52.0 52.0
Disease related death 28.6 28.1  16.4 15.7  17.7 15.1
Non-disease related death 3.6 3.0  8.5 7.8  41.7 36.9
         
Recurrent disease or death 41.5 41.5  32.2 32.2  58.7 58.7
Recurrent disease 39.5 38.8  26.8 25.8  26.3 22.4
Death without recurrent disease 3.2 2.7  7.5 6.5  43.8 36.2
 
KM: Kaplan-Meier method; CR: competing risk analysis. Recurrent disease was defined as either local 





Contralateral breast cancer 
 
We evaluated the effect of the inclusion of contralateral breast cancer as event in 
the analysis of disease recurrence on estimated disease free interval and disease 
free survival (Table 3.3). The administration of adjuvant systemic therapy is 
known to reduce the risk of contralateral breast cancer.12,13 In the whole study 
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population the absolute reduction in disease free survival or disease free interval 
due to inclusion of contralateral breast cancer as event in the definition of relapse 
was approximately 4%; in patients not treated with adjuvant systemic therapy 6-
7%, and in patients treated with adjuvant systemic therapy 1-2%. In the broadest 
definition of relapse 197 events were counted during 10-years follow-up, including 
47 non-disease related deaths and 26 contralateral breast cancers. That is, in the 
analysis of disease free interval 17% of events were contralateral breast cancers, 
compared with 13% in the analysis of disease free survival. Consequently, the 
effect of the inclusion of contralateral breast cancer as event in the definition of 
relapse was greater when estimating disease free interval than when estimating 
disease free survival (Table 3.3).  
 
Similarly, the greatest effect of the inclusion of contralateral breast cancer and 
non-disease related death as events on estimated disease recurrence rate was 
found in patients with low risk breast cancer. In a subgroup of 168 patients with 
T1N0 breast cancer, not treated with adjuvant systemic therapy, the 10-year 
relapse rate including local relapse, regional relapse, or distant metastasis was 
23%. The estimated 10-year relapse rate rose to 31% both with the inclusion of 
either contralateral breast cancer or non-disease related death as event in the 






In the present study we show in a cohort of patients with early breast cancer that 
the inclusion of contralateral breast cancer or non-disease related death as event 
in the definition of recurrent disease or survival strongly affects estimated 
outcome probability. The magnitude of the effect is dependent on patient-, 
tumour-, and treatment characteristics. 
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These findings, and the explicit definition of outcome seem of minor importance 
for the interpretation of a particular clinical trial as long as results are not 
compared with other trials. After all, all study arms use the same definition(s) of 
outcome. However, the effect of the intervention can be different for the various 
events that are counted, ignored or censored in the definition of outcome. As a 
consequence, the in- or exclusion of contralateral breast cancer or non-disease 
related death in the definition of outcome could influence the results of a trial. We 
can illustrate this with data from the Anastrozole, Tamoxifen, Alone or in 
Combination (ATAC) trial.14,15 6241 patients are included in the 2 relevant arms of 
this trial. After a median follow-up of 68 months, 831 patients have died (411 
patients treated with anastrozole and 420 patients treated with tamoxifen). More 
patients who were treated with tamoxifen died from breast cancer than patients 
who were treated with anastrozole (265 vs. 235), whereas fewer patients who 
received tamoxifen died from a cause not related to breast cancer (155 vs. 176). 
Treatment with anastrozole also led to a reduction in disease recurrences (402 
vs. 498). A considerable part of this reduction was caused by the difference in 
occurrence of contralateral breast cancers (35 vs. 59). Consequently, anastrozole 
led to an improvement in disease free survival (Hazard Rate (HR) 0.87, p=0.01), 
and an even better improvement in disease free interval (HR 0.79, P=0.0005). 
Overall survival was similar for anastrozole and tamoxifen treated patients (HR 
0.97), whereas disease specific survival was 12% better in the anastrozole group, 
although this was not significant (HR 0.88, p=0.20). These data from the ATAC 
trial illustrate that a clear definition of survival endpoints, including the contribution 
of non-disease related death and the contribution of contralateral breast cancer to 
the estimated disease recurrence rate are crucial for a correct interpretation of 
outcome analyses in clinical trials. These data also demonstrate that a significant 




The Kaplan-Meier method for estimating survival has repeatedly been criticised 
for possible biases in the estimation of event rates.9,11,16 In the presence of 
competing events, cumulative incidence functions of the events of interest are 
probably evaluated more appropriately by taking into account other events within 
a competing risk framework. In general, event rates derived using the Kaplan-
Meier approach are larger than estimates accounting for competing risks,9,11 and 
differences between Kaplan-Meier and competing risk approaches can become 
substantial when the competing risk event is related to or is a result of the 
underlying disease. But, as presented by Satagopan et al., ignoring the 
informative censoring mechanism does not substantially influence the estimates 
of breast cancer-specific mortality.9 We present similar results in our estimations 
of disease-specific survival and disease free survival. However, differences 
became more substantial when relative more patients were censored due to 
competing events. 
 
In conclusion: Clear definitions of endpoints and competing events are crucial for 
the interpretation and comparison of outcome studies. In the present study on 
patients with early breast cancer, the inclusion of contralateral breast cancer 
and/or non-disease related death substantially influenced estimates of recurrent 
disease rate and survival, specifically in elder patients and patients with a good 
prognosis. Bias generated by the Kaplan-Meier approach due to informative 
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ABSTRACT 
 
Background: The main reason to determine the oestrogen (ER) and 
progesterone receptor (PR) in breast cancer is their predictive value for response 
to endocrine therapy. In addition, ER and PR receptors are often used as 
prognostic indicators. Enzyme immuno assay (EIA) and immunohistochemistry 
(ICA) are two methods for determining ER and PR receptors. These two methods 
have not been compared to each other on clinical endpoints. 
 
Methods: In the present study we prospectively evaluated the prognostic value 
of ER and of PR, as determined both by ICA and by EIA, in 223 and 207 patients, 
respectively with early breast cancer. 
 
Results: ER was positive in approximately 77% of patients, PR was positive in 
approximately 65% of patients. The proportion of potential agreement beyond 
chance between EIA and ICA was 0,58 and 0,65 for ER and PR respectively. The 
median follow-up period was 86 months. Both ER and PR appeared to be weak 
prognostic factors. No differences in prognostic value according to time-point of 
analysis or cut-off value chosen were found. No differences in prognostic value of 
hormone receptors detected by ICA or EIA were found.  
 
Conclusions: Both methods appear to be equivalent with respect to 







Oestrogen- (ER) and progesterone-receptors (PR) are routinely used in the 
clinical management of breast cancer. The main reason to determine ER and PR 
is their predictive value for response to hormonal therapy.1,2 It has been noted 
that oestrogen- and progesterone-receptors are also weak prognostic factors. 
However, long-term disease free and overall survival are not significantly 
influenced by the hormone receptor status.3  
 
There are three commonly used techniques for hormone receptor determination. 
Until recently the ligand binding assay (LBA) has been the most commonly used 
method. With this method the rates of binding affinity and capacity of a 
radioactively labelled steroid hormone with its receptors in cytosol are measured. 
Nowadays most hospitals in the Netherlands use immunocytochemical assays 
(ICA) for determination of the presence of hormone receptors in tumour cells. 
With this qualitative technique highly specific monoclonal antibodies directed 
against the partially purified receptor are used. ICA has advantages over LBA: it 
is more sensitive and specific in the identification of low concentrations of 
hormone receptor positive tumour cells or in identifying hormone receptors in 
benign epithelium under direct microscopic visualization.4,5 Several efforts have 
been made to (semi-)quantify ICA results. Good intra- and inter-observer 
reproducibility have been reported.6,7 McClelland et al., however, compared the 
quantitative analyses of eight experienced, independent pathologists in the 
interpretation of ER and PR immunocytochemically stained breast tumour 
sections and observed a high interobserver variability.8 The method of enzyme 
immunoassay (EIA) also uses specific monoclonal antibodies for hormone 
receptor determination, but in a quantitative way. It therefore shares many of the 
advantages of LBA and ICA. However, it lacks the control of presence or absence 
of receptor proteins in tumour cells. Concordance rates of 75% - 85% and 
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correlation coefficients of 0.70 – 0.97 between EIA, ICA and LBA have been 
reported and are found to be acceptable.5-7,9-17 
 
The predictive and prognostic values both of EIA and of ICA appear of the same 
magnitude compared with that of LBA.11,18,19 The prognostic value of ICA and EIA 
have not been compared with each other. To our knowledge there has been only 
one study comparing the predictive value of EIA and ICA.15 In the present study 
we prospectively evaluated the prognostic value detected both by ICA and by EIA 




PATIENTS AND METHODS 
 
Patients and primary treatment 
 
In 5 hospitals affiliated with the Comprehensive Cancer Centre Middle 
Netherlands (IKMN) patients with operable breast cancer, diagnosed between 
October 1989 and March 1993, were asked to participate in a registration study 
on prognostic factors. 463 patients with stage I-III breast cancer gave their written 
informed consent. Follow-up information from all patients was collected until 
August 1999. ER-ICA, ER-EIA, PR-ICA and PR-EIA were determined in this 
multicentre study in 328, 337, 318 and 321 patients respectively. ER-ICA as well 
as ER-EIA was determined in 223 patients. Both ER-ICA and ER-EIA were not 
determined in 21 patients. PR-ICA as well as PR-EIA was determined in 207 
cases. Both PR-ICA and PR-EIA were not determined in 30 patients. Survival 
analyses for ER and PR were performed on these 223 and 207 patients, 
respectively. Analyses were also performed on those patients in whom hormone 






EIA for specimens from all institutions was performed at the department of 
Endocrinology of the University Medical Centre Utrecht. Cytosols were prepared 
according to the EORTC procedure.20 EIA was performed according to the 
instructions of the manufacturer (Abbott Laboratories, Chicago, IL, USA). Briefly, 
cytosol was incubated with beads coated with an anti-receptor monoclonal 
antibody (H222 for ER and KD68 for PR). Unbound material present in the cytosol 
was removed by aspirating the fluid and washing the beads. A second 
monoclonal anti-receptor antibody conjugated with horseradish peroxidase 
detected the presence of immune reactions in standards, controls, and cytosol 
samples. The chromogenic substrate was represented by orthophenylendiamine, 
developing a colour that was analysed by a spectrophotometer at 492 nm. and 
allowed a measurement of bound receptor conjugate, expressed as fmol/mg 
protein. Specimens with receptor values > 15 fmol/mg protein were considered 




ER- and PR-determination by ICA were performed at the local pathology 
department on fresh frozen tumour-tissue. ER-ICA and PR-ICA were performed 
according to the instructions of the manufacturer (Abbott Laboratories, Chicago, 
IL, USA) using monoclonal rat antibodies to respectively human ER and PR. 
Tumours were considered hormone receptor positive if more than 10% of tumour 
cells showed positive staining.11,12,16 In this study ICA data were obtained from 
routine pathology reports and are therefore reported as positive or negative. 
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Number of patients 240 223  256 207  
      
Primary surgical treatment      
Modified radical mastectomy 38% 43%  39% 43%  
Breast conserving therapy 60% 55%  59% 55%  
Local excision only 2% 2%  2% 2%  
       
Radiation therapy 67% 64%  67% 64%  
       
Adjuvant chemotherapy 15% 16%  15% 16%  
       
Adjuvant hormonal therapy 27% 35% † 28% 35%  
       
Tumour diameter       
0 – 10 mm. 22% 11% ƒ 22% 10% ƒ
11 – 20 mm. 35% 48%  35% 49%  
> 20 mm. 38% 40%  38% 41%  
Unknown 5% 1%  5% 0%  
      
Axillary lymph node status      
Tumour negative 61% 55%  60% 56%  
Tumour positive 38% 43%  38% 43%  
Unknown 2% 2%  2% 2%  
       
Age       
0 – 45 years 18% 19%  18% 20%  
46 – 55 years 31% 26%  29% 27%  
56 – 70 years 33% 32%  33% 31%  
> 70 years 19% 23%  19% 22%  
 






Statistical analysis was carried out using the statistical package SPSS for 
Windows, release 9.0 (SPSS Inc.). Kappa statistics were used to measure the 
degree of agreement as determined by the two methods. Univariate associations 
between hormone receptor-status by ICA or EIA and control groups, treatment 
modalities and other categorized prognostic variables were assessed by the 
Pearson chi-square test. Endpoints of the study were disease free survival (DFI) 
and overall survival (OS). For DFI time to failure was computed from the date of 
surgery until recurrence (loco regional recurrence or distant metastasis) or until 
the last date patient was known to be free of disease. Patients who developed 
contralateral breast cancer were censored at the date of diagnosis. Patients who 
died from a cause not related to breast cancer were censored at the date of 
decease. Overall survival was calculated from the date of surgery until death or 
until the date the patient was last known to be alive. Univariate analyses were 
performed with life tables and with the time-fixed Cox regression procedure. For 
survival analyses follow-up was truncated at 84 months. Events that took place 





In the present registration study 463 patients were suitable for survival analysis. 
Both ER-EIA and ER-ICA were determined in 223 patients. The remaining 240 
patients were used as control group in order to exclude selection bias. Both PR-
EIA and PR-ICA were determined in 207 patients; the other 256 patients were 
used as a control group. Treatment modalities and tumour characteristics in the 
study groups were compared with those of the control groups (Table 4.1). Breast 
conserving therapy was performed in 55% - 60%, mastectomy in 38% - 43% of 
patients. Local excision only was done in 2% of patients. Radiation therapy was 
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Table 4.2. Percentages hormone-receptor positive tumours according to tumour characteristics and 
adjuvant treatment modalities.  
 





        
 ER-ICA ER-EIA  PR-ICA  PR-EIA  
        
Total 77% 78%  67%  63%  
        
Adjuvant chemotherapy        
Yes 75% 72%  71%  76%  
No 77% 79%  66%  60%  
       
Adjuvant hormonal therapy       
Yes 80% 85%  63%  57%  
No 75% 74%  70%  66%  
        
Tumour diameter        
0 – 10 mm. 58% 58% † 38% § 38% ‡ 
11 – 20 mm. 81% 83%  75%  70%  
> 20 mm. 75% 79%  64%  60%  
       
Axillary lymph node status       
Tumour negative 72% 73%  63%  60%  
Tumour positive 81% 83%  72%  65%  
        
Age        
0 – 45 years 67% 67%  68%  68%  
46 – 55 years 74% 76%  73%  71%  
56 – 70 years 77% 77%  56%  55%  
> 70 years 86% 90%  74%  59%  
 




administered in 64% - 67% of patients, and adjuvant chemotherapy in 15% - 16% 
of patients. The percentage of patients that received adjuvant hormonal therapy 
was higher in the groups in whom both ER-EIA and ER-ICA were determined 
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compared to the control group, 35% vs. 27%. Of 21 patients in whom ER was not 
determined by ICA or EIA, 7 (33%) received adjuvant hormonal therapy. In the 
study group hormonal therapy was not given significantly more in ER-positive 
tumours compared to ER-negative tumours (table 4.2). The control groups 
contained significantly more small tumours with a diameter < 11 mm compared to 
the study groups (22% vs. 11%). In all groups almost 60% of tumours were less 
than 2 cm in diameter, 55% - 61% of tumours were axillary lymph node negative. 
 
 
Table 4.3. 2 x 2 tables ICA and EIA. 
 
ER-ICA   
Negative Positive Total 
Negative 34 15 49  
ER-EIA Positive 18 156 174 
 Total 52 171 223 
 
PR-ICA   
Negative Positive Total 
Negative 56 21 77  
PR-EIA Positive 12 118 130 





Median ER-EIA value was 101 fmol/mg protein (range 0 – 1975); median PR-EIA 
value was 44 fmol/mg protein (range 0 – 1985). ER-EIA and ER-ICA were 
positive in 174 (78%) and 171 (77%) cases, respectively. PR-EIA and PR-ICA 
were positive in 130 (63%) and 139 (67%) cases, respectively. Small tumours (< 
11 mm.) were significantly less often ER- or PR-positive compared to larger 
tumours (Table 4.2). The proportion of potential agreement beyond chance 
(Kappa) between EIA and ICA was moderate to substantial. Results from ER-EIA  
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Figure 4.1. Oestrogen receptor and disease free interval (A and B) and overall survival (C and D). 
Solid line: receptor positive tumours; dotted line: receptor negative tumours. ER-ICA: A and C; ER-
EIA: B and D. 
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and ER-ICA agreed in 85% of cases (Kappa 0.58). Results from PR-EIA and PR-
ICA agreed in 84% of cases (Kappa 0.65). Two by two tables are depicted in 
table 4.3. Immunohistochemistry of discordant specimens from one of the three 
pathology departments was re-examined. None of 7 ER-ICA negative and 6 PR-
ICA negative marked specimens were converted to positive, 1 of 4 ER-ICA 
positive and 1 of 4 PR-ICA positive marked specimens were converted to 
negative (the cells that were stained positive were interpretated as carcinoma in 
situ). Unfortunately we were not able to re-evaluate EIA measurements. 
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The median follow-up was 86 months (range 44 – 110). For survival analyses 
follow-up was truncated at 84 months. During 84 months of follow-up 17% - 20% 
of patients died, 12% - 14% died related to breast cancer. Contra-lateral breast 
cancer was diagnosed in 3% - 5% of patients. In 23% of patients breast cancer 
relapsed. Distant metastases were diagnosed in 19% - 20% of patients, loco-
regional relapses in 7% - 10% of patients. The rate of events did not differ 
significantly between study- and control-groups. DFI and OS did not differ 
significantly between study- and control-populations. After 84 months of follow-up 
ER-ICA, ER-EIA and PR-ICA were significant prognosticators of OS. Significance 
remained after stratification for adjuvant hormonal therapy. No significance was 
found for DFI after 7 years (Figure 4.1 and 4.2). EIA measurements were 
quantitative. The prognostic significance of ER-EIA and PR-EIA as continuous 
variables was determined. No significance was found for DFI or OS. Three, 5 and 
7 year DFI- and OS-rates were determined and compared (Table 4.4). No 
differences were found between study- and control groups. Three, 5 and 7 year 
DFI was 86%, 81% and 75% respectively. DFI-rates in hormone receptor positive 
patients were slightly higher compared to hormone receptor negative patients. 
These differences were not statistically significant. Three, 5 and 7 year OS was 
93%, 87% and 80% respectively. Differences between OS-rates in hormone 
receptor positive and negative patients were greater and frequently statistical 
significant (Table 4.4). 
 
In continuous variables the cut-off level used for survival analysis can be chosen 
at an arbitrary level. The cut-off level for EIA of 15 fmol/mg protein used in the 
present study was advised by the manufacturer of the antibodies. Other cut-off 
values were studied (Figure 4.3). The relative risk of disease free survival of 
patients with EIA negative- compared to EIA positive tumours varied between 0.4 
and 1.1 for ER, and between 0.5 and 1.0 for PR. The relative risk of overall 
survival of patients with EIA negative- compared to EIA positive tumours varied  
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Figure 4.2. Progesterone receptor and disease free interval (A and B) and overall survival (C and 
D). Solid line: receptor positive tumours; dotted line: receptor negative tumours. PR-ICA: A and C; 
PR-EIA: B and D. 
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between 0.5 and 0.6 for ER, and between 0.3 and 0.7 for PR. The differences in 





Both EIA and ICA are commonly used methods for determining hormone 
receptors in breast cancer. The main purpose to determine hormone receptors is 
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their ability to predict efficacy of endocrine therapy. But hormone receptors are 
also used as a prognostic indicator. We have prospectively compared the 
prognostic value of the oestrogen- and progesterone receptor values as 
determined by ICA and EIA in a routine clinical setting. 
 
Between 1989 and 1993 in total 463 early breast cancer patients were included in 
a multicentre, prospective registration study on prognostic factors. ER and PR 
could be determined both by EIA and by ICA in less than 50% of patients (48% 
and 45% respectively). In order to evaluate a potential bias, the remaining 
patients in whom ICA and/or EIA were not determined were used as a control 
group. Most tumour characteristics and primary treatment modalities differed not 
significantly between the study and the control groups. However, the percentage 
of patients that received adjuvant hormonal therapy was higher in the ER-study 
group compared with that of the ER-control group. We could not find a suitable 
explanation for this phenomenon. Treatment selection based on hormone 
receptor values is not likely since hormonal therapy was not given significantly 
more in ER-positive tumours compared with that of ER-negative tumours. In 
tumours in which the ER was not determined at all, hormonal therapy was 
provided to 33% of patients. At the time of patient inclusion hormone receptors 
were not used as predictive factor. The rate of small tumours (< 11 mm.) was 
significantly higher in the control groups compared to the study groups. This was 
at least partly due to selection, since it is not possible to perform an adequate and 
reliable EIA in micro-invasive cancer. However, the consequences of this bias 
appear to be low. During follow-up the rate of events did not differ significantly 
between study- and control groups. No differences in Cox-regression analyses 
and in 3, 5 and 7 year survival rates were found between study- and control 
groups either. Therefore, we conclude that the groups of patients in whom ER 
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Table 4.4. Three, 5 and 7 year disease free interval and overall survival.  
 
 Cumulative disease free interval
 
Cumulative overall survival 








































            



























            























































            



























            

































Figure 4.3. Relative risk of disease free- and overall survival (solid line) with 95% confidence 
interval (dotted lines) at progressively higher cut-off values for ER-EIA and PR-EIA. 
 




































































The oestrogen receptor was positive in approximately 77% of patients, the 
progesterone receptor was positive in approximately 65% of patients. The 
proportion of potential agreement beyond chance between EIA and ICA was 
moderate to substantial (Kappa 0,58 and 0,65 respectively for ER and PR). These 
results are in line with that of the literature.7,10,11,13,15-17,21-23 Concordance between 
EIA and ICA found in the present study was substantial (85%), but there also 
were a substantial number of tumours with a discordant result. Re-evaluation of 
22 ICA samples, with discordant EIA/ICA results, led to only 2 conversions. 
Unfortunately it was not possible to re-evaluate EIA samples. Explanations for 
discordant EIA/ICA results are: effect of fixation and processing on the 
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preservation of hormone receptors,24 intratumoural heterogeneity,12,13 improper 
handling of the specimens or unsuitable samples of the tumour sent for EIA,12 
hormone receptor positive benign- or intraductal components in the EIA sample,12 
borderline EIA and ICA results.13 The major theoretical advantage of ICA over EIA 
is microscopic verification of the presence of the receptor proteins in tumour cells. 
It has been suggested that ICA is a more specific and more sensitive test for the 
measurement of receptor content in breast cancer.12 It is, however, impossible to 
draw conclusions concerning specificity and sensitivity and the discordant results 
in the present study. 
 
After 7 years of follow-up ER-ICA, ER-EIA and PR-ICA were significant 
prognosticators of OS. Significance remained after stratification for adjuvant 
hormonal therapy. No significance was found for DFI though. The absence of 
prognostic significance in the present study for DFI was not unexpected. The 
number of patients studied was relatively small. ER and PR are considered to be 
weak prognostic factors.2 The observed prognostic significance of the hormone 
receptors for OS was probably caused by a better response in relapsed disease 
to hormonal treatment of patients with initial hormone receptor positive tumours. 
 
Although long-term DFI and OS are thought not to be significantly influenced by 
the hormone receptor content, hormone receptor positive tumours are thought to 
have a somewhat more indolent course during the first few years after primary 
treatment.2 This could not be supported by the differences in DFI-rate and OS-
rate between hormone receptor negative and positive tumours at 3, 5 and 7 year, 
as they appeared to be constant over time and independent upon time-point of 
analysis. 
 
The major theoretical advantage of EIA over ICA is its objective quantification. 
Several efforts have been made to (semi-)quantify ICA results and good intra- 
and inter-observer reproducibility has been reported by several authors.6,7 Others, 
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however, observed a high interobserver variability.8 In the present study ICA-
results were binominal, no efforts were made to (semi)quantify ICA using a 
scoring system in order to reflect the routine clinical practice. The cut-off value 
was arbitrarily chosen at 10% staining. Results from EIA were quantitative. The 
cut-off value chosen to separate receptor-negative from receptor-positive tumours 
was 15 fmol/mg protein, according to the instructions of the manufacturer of the 
antibodies. But, the prognostic value of continuous variables, such as ER and PR, 
may be influenced by the cut-off level chosen.25 Therefore, other cut-off values 
were studied. No significant differences in prognostic value of different cut-off 
values were found. 
 
To our knowledge there has been only one study comparing the predictive value 
of EIA and ICA .15 No former studies have been conducted comparing the 
prognostic value ER and PR as determined by either EIA or ICA. In the present 
study we prospectively evaluated the prognostic value detected both by ICA and 
by EIA of ER in 223 and of PR in 207 breast cancer patients after a median 
follow-up of 86 months. Both ER and PR appeared to be weak prognostic factors. 
No differences in prognostic value according to time-point of analysis or cut-off 
value chosen were found. No differences in prognostic value of hormone 
receptors detected by ICA or EIA were found. Both methods appear to be 
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Prognostic value of mitotic counts in axillary 
node negative breast cancer patients with 
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Background: In axillary node negative (ANN) breast cancer patients additional 
prognostic markers are needed to decide whether adjuvant systemic treatment 
might be useful. 
 
Methods: In the present study the prognostic relevance of mitotic counts and 
Bloom-Richardson grade (BR-grade) was evaluated in 164 ANN breast cancer 
patients. No adjuvant systemic treatment was given to any of these patients. 
Mitotic counts were determined twice, in routine practice and in revision. 
 
Results: A substantial reproducibility of mitotic counts was found, provided that 
the cut-off value chosen was high enough. After a median follow-up of 10 years, 
mitotic counts had no prognostic significance for survival at any cut-off value. A 
trend towards a significant worse survival was found for patients with Bloom-
Richardson grade II or III in comparison with grade I. 
 
Conclusions: Based on data in the literature a positive association between 
both mitotic counts and Bloom-Richardson grade and survival in axillary node 
negative breast cancer may exist, but the extent of this putative association and 
its clinical relevance can be argued, particularly in a group of patients with 





A number of guidelines for the adjuvant systemic treatment of axillary node 
negative (ANN) breast cancer have been published.1-3 In these guidelines tumour 
size is used to decide whether adjuvant systemic treatment is indicated. However, 
in patients with tumours of intermediate size other prognostic factors are needed 
to define low or average/high risk subgroups. A number of markers have been 
suggested for this purpose. However, with the exception of histological grade, the 
clinical relevance of these markers specifically in ANN breast cancer is not 
established. 
 
Proliferative capacity is important in the progression of cancer and mitotic counts 
(MC) represent tumour cell proliferation. MC are also an important component of 
all histological grading systems. In the present study we evaluated the 
reproducibility and prognostic relevance of MC and Bloom-Richardson grade (BR-
grade) in 164 ANN breast cancer patients. No adjuvant systemic treatment has 
been administered to these patients. The objective was to determine whether 
either MC or BR-grade could be used to determine a subgroup of ANN breast 
cancer patients in whom adjuvant systemic treatment might result in a clinically 
relevant increase of survival. 
 
 




In 5 hospitals affiliated with the Comprehensive Cancer Centre Middle 
Netherlands (IKMN) consecutive patients with operable, stage I to III breast 
cancer, diagnosed between October 1989 and March 1993, were asked to  
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Table 5.1. Patient and treatment characteristics of eligible and non-eligible patients with negative 
axillary lymph nodes. 
 
 Number of patients  





Age median (range) 58  61  
< 50 years 48  26  
50 – 59 years 45  27  
60 – 69 years 37  33  
≥ 70 years 34  25  
   
Primary treatment   
Modified radical mastectomy 55  37 
Breast conserving therapy 108  68  
Other 1  6  
   
Histological type   
Ductal carcinoma 126  83  
Lobular carcinoma 17  9  
Mixed type 8  6  
Other 13  13  
   
Tumour size   
< 11 mm 31  36  
11 – 30 mm 117  67  
> 30 mm 15  8 
Unknown 1  0  
 
 
participate in our study. From 463 patients we obtained written informed consent. 
In the present study we specifically focused on ANN breast cancer patients 
(n=275). Not included were 38 (14%) patients who received adjuvant systemic 
therapy. Another 58 tumours were non-eligible because we were unable to 
acquire the exact routine MC from the pathology reports. Finally, specimens from 
14 tumours could not be retrieved for revision and of 1 specimen fixation quality 
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was found not good enough to revise MC. So, eligible were 164 ANN breast 
cancer patients who received no adjuvant systemic therapy and in whom MC 
were performed both in routine practice and in revision. Patient- and treatment 
characteristics of the eligible patients and non-eligible ANN breast cancer patients 
were comparable and are shown in Table 5.1. The study was performed in a 
period when mammographic screening was systematically practiced in the IKMN 
district for patients between 50 and 70 years of age. Follow-up was assessed until 




MC were determined routinely in three pathology departments. Data were 
obtained from the pathology reports. Routine MC were determined using 
microscopes with a 400x magnification, a 40x objective and a field area of 159 
μm2. Mitoses were counted in 10 consecutive high power fields. The MC were 
revised according to the criteria proposed by Baak and Clayton.4-8 In most cases it 
was clear which slide was initially used for mitosis counting. In some cases we 
had to re-select a slide from the provided material. The quality of the provided 
sections varied, but was interpreted as good in the majority (91%) of cases. MC 
were revised using a microscope with a 400x magnification, a 40x objective and a 
field area of 310 μm2. Mitoses were counted in 20 consecutive fields. Two 
observers (EF, FB) evaluated the sections simultaneously. In this study the MC 
were defined as the number of mitoses per 2 mm2, instead of the number of 
mitoses per 10 high power fields. This was done in order to overcome the variety 
in field sizes of the various microscopes used. 
 
Modified Bloom-Richardson grade 
 
In all revised cases histological grade was evaluated using the modified Bloom 
Richardson grading system as proposed by Elston and Ellis.9 In this grading 
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system three parameters: tubule formation, nuclear pleomorphism, and MC are 
determined. To each parameter a score of 1 to 3 is assigned. The final BR-grade 
is based on the summed score of these three parameters. For the MC Elston and 
Ellis used a field area of 274 μm2. Up to 9 mitoses per 10 fields scored 1 point, 
10-19 scored 2 points and more than 20 scored 3 points. This point system was 
recalculated from mitoses per 2.74 mm2 (10 x 274 μm2) to mitoses per 2 mm2: Up 
to 7 mitoses per 2 mm2 scored 1 point, 8 - 14 scored 2 points and more than 14 




Statistical analysis was carried out using the statistical package SPSS for 
Windows, release 10.0 (SPSS Inc.). Correlations between routine and revised MC 
were assessed using the nonparametric Spearman test. The agreement and the 
proportion of potential agreement beyond chance that was actually achieved 
(Kappa) between routine and revised MC were determined using cut-off values 
ranging from 4 to 18 mitoses / 2 mm2. Association between MC and BR-grade 
was assessed using the Kruskal-Wallis test. Univariate and multivariate survival 
analyses were performed with the time-fixed Cox regression procedure. Survival 
endpoints of the study were disease free survival (DFS), distant metastasis free 
survival (DMFS) and overall survival (OS). For DFS time to failure was computed 
from the date of surgery until relapse or until the last day patient was known to be 
disease free. For DMFS time to failure was computed from the date of surgery 
until distant metastasis or until the last day patient was known to be free of distant 
metastasis. Patients who died during follow-up were censored at the date of 
death. Patients who developed contra-lateral breast cancer were censored at the 
date of diagnosis. OS was calculated from the date of surgery until death or until 








The mean and median MC measured routinely and after revision are listed per 
pathology department in table 5.2. Mean and median values were comparable 
between the 3 pathology departments and between routine and revised 
evaluation. In the revised evaluation significantly higher maximum MC were 
scored than in routine evaluation. In the revised specimens the BR-grade was 
determined as well (Table 5.2). Seventy-four tumours (45%) were histological well 




Table 5.2. Routine and revised mitotic counts and Bloom-Richardson grade according to pathology 
department. 
 
 Pathology department 
 A B C 
    
Number of patients 62 50 52 
    
Routine mitotic counts    
Median (range) 7 (1-47) 6 (0-44) 8 (0-54) 
Mean 11 10 12 
    
Revised mitotic counts    
Median (range) 7 (0-92) 6 (0-85) 5 (0-91) 
Mean 11 12 12 
    
Bloom-Richardson grade    
I 45% 40% 50% 
II 44% 34% 29% 
III 11% 26% 21% 
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Routine and revised MC correlated well (r = 0.76, p < 0.001). The observed 
agreement between routine and revised MC varied between 0.76 and 0.90, kappa 
varied between 0.37 and 0.66, depending on the cut-off value used. Kappa was 
lower specifically when lower cut-off values were used. BR-grade and MC were 
strongly associated (p<0.0001). Median revised MC was 3 per 2 mm2 in grade I 




During follow-up 36 patients had recurrent disease (28 patients with distant 
metastases) and 37 patients died (23 deaths were caused by breast cancer). 
After 5 year DFS was 83% (DMFS 86%), OS was 90% (disease specific survival 
94%). After 10 year DFS was 76% (DMFS 81%), OS was 77% (disease specific 
survival 85%). 
 
The prognostic value of revised MC for DFS, DMFS and OS was analysed. 
Hazard ratios were determined using progressively higher cut-off values. 
Significance was not found for DFS, DMFS or for OS at any cut-off value. 
Comparable results were found when the analyses were performed on routine 
MC or were restricted to patients younger than 70 years of age, tumours 11 to 30 
mm in diameter, or ductal carcinomas only (data not shown). As an example 
Figure 5.1 shows the overall survival curves according to revised MC using 13 
mitoses / 2 mm2 as cut-off value (Figure 5.1). 
 
The risk for relapse (including loco-regional relapses) did not differ significantly 
between well, moderately and poorly differentiated tumours. The risk for distant 
metastasis was highest in patients with poorly differentiated tumours, but not 
significantly different from that of patients with well-differentiated tumours 
(p=0.12). Patients with moderately differentiated tumours had a significant higher 
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risk (p=0.04, RR 2.2) for death than patients with well-differentiated tumours 
(Figure 5.2). 
 
In multivariate analysis including age, tumour size, BR-grade and MC, age was 





In published studies on MC in breast cancer the MC are usually expressed as 
number of mitoses per 10 high-power fields. But, these high-power fields are not 
uniformly defined. The area of the high-power fields used, if mentioned at all, 
varies from 0.102 mm2 to 0.216 mm2.10,11 Consequently interpretation of results is 
difficult. To overcome this problem we have defined MC as the number of mitotic 
figures per 2 mm2. 
 
In the present study the median MC was 6 mitoses per 2 mm2. In other reports 
the median MC (recalculated into mitoses per 2 mm2) varied from 2.7 to 13.9 
mitoses per 2 mm2.4,8,10-12 This variation can probably be explained by differences 
in patient characteristics: Tumours detected by screening have lower MC and MC 
in ANN patients are lower than those in node positive patients.11,13 But, the 
observed wide variation in median values of MC also may suggest a low 
interobserver (or intergroup) reproducibility. 
 
To assess the reproducibility of MC we have revised tumour samples from 164 
patients. The MC were initially determined in routine practice at 3 separate 
pathology departments. The correlation coefficient found between routine and 
revised MC was 0.76. Bergers et al. found slightly better correlations.14 The 
correlation coefficients found by van Diest et al. were much better with an overall r 
of 0.91.7 But, in that study the counting areas were marked, which might explain  
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Figure 5.1. Overall survival according to mitotic counts using 13 mitoses / 2 mm2 as cut-off value. 
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the higher correlation coefficients.15 The reproducibility of MC is said to depend 
on the quality of the slides and on the pathologist’s interpretation.5 In our opinion 
the correlation coefficient of 0.76 is a good reflection of the reproducibility of MC 
obtainable in routine practice. The wide variation in median MC found among the 
investigational groups can probably be explained by a poor agreement between 
them in the recognition and/or interpretation of (abnormal) mitoses.16 
 
For survival analyses the MC are often dichotomised, but the cut-off value used 
and proposed for this purpose varies. In dichotomised variables kappa is a 
measure of reproducibility. The reproducibility of the MC is smaller when the 
number of mitotic figures counted is smaller.17 In the present study a substantial 
kappa (> 0.60) was reached when the cut-off value used was at least 6 mitoses 
per 2 mm2. Reproducibility of MC and, as a consequence, its prognostic value  
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Figure 5.2. Overall survival according to Bloom-Richardson histological grade. 
 

































declined when lower cut-off values were used. Therefore, the cut-off value used 
must be sufficiently high to obtain reproducible and reliable analyses of the 
prognostic value of MC. 
 
Mirza et al. have recently reviewed the published literature on prognostic factors 
in patients with ANN breast cancer, focusing principally on recent studies with 
large sample sizes and extended follow-up periods.18 Four studies were identified 
that assessed the prognostic value of MC for decreased survival.8,19-21 We have 
found three more studies.22-24 In the present study no significant association 
between MC and survival was found, but the number of events (relapse and 
death) was relatively low. The strongest association between MC and DFS or OS 
in ANN breast cancer was reported by van Diest and Baak.24 But the number of 
patients and events in that study was low. Clayton showed a positive association 
between MC and DSS in a study with sufficient events.8 But, in that study the 
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median value for the MC was low, which might have had a negative influence on 
reproducibility.17 In the largest study, performed on 1028 patients with T1N0 
breast cancer, no significant association between MC and survival was found.23 
Page showed a significant association between MC and OS only when the 
analysis was restricted to the first 5 years of follow-up.22 The association 
disappeared with longer follow-up time. In the study performed by Aaltomaa DFS 
and DSS were positively associated with MC, but DFS could not be predicted by 
MC in patients with tumours ≤2 cm in diameter.19 Based on these studies we 
submit that a positive association between MC and survival in ANN breast cancer 
may exist, but that the extent of this putative association is a matter of debate. 
The extent probably depends on other tumour characteristics such as tumour size 
and histological grade. 
 
In the present study a trend towards a significantly worse survival was found in 
patients with poorly or moderately differentiated tumours compared with patients 
with well-differentiated tumours. The number of well-differentiated tumours was 
relatively large (45%). In the study performed by van Diest only 12% of ANN 
tumours were well differentiated. In that study no significant association between 
BR-grade and OS was found, in contrast to a strong association between MC and 
OS.24 In the studies performed by Aaltomaa, Clahsen, Clayton and Page the BR-
grade was positively associated with DSS and OS respectively.8,19,21,22 In the 
studies performed by Aaltomaa and Clayton the MC were slightly better in 
predicting DSS. In the studies performed by Clahsen and Page the BR-grade was 
slightly better.  
 
In conclusion the determination of MC is an inexpensive, fast and reproducible 
way of assessing proliferation in routine practice. But, apparently, there is a poor 
agreement between the different investigational groups in the recognition and/or 
interpretation of (abnormal) mitoses. When cut-off values are used for survival 
analyses, they must be sufficiently high to obtain reproducible and reliable 
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analyses. Based on data in the literature it is likely that in patients with ANN 
breast cancer the MC are positively associated with survival, but the extent of this 
association can be a matter of debate. In the present study no significant 
association between MC and a number of relevant survival end-points was found. 
The favourable tumour characteristics and the associated low number of events 
can probably explain this. The prognostic value of the BR-grade is likely to be 
comparable to that of the MC. In the present study a trend towards a significant 
worse survival was found in patients with grade II or III tumours compared with 
patients with grade I tumours. In ANN breast cancer patients the prognostic value 
of the BR-grade may be superior to MC if the tumours are predominantly well 
differentiated, whereas MC may be superior to BR-grade if the tumours are 





The authors wish to thank drs. M.E.I. Schipper, dr. H.M. Ruitenberg and dr. A. 
Hennipman for their help with this study. They thank the Comprehensive Cancer 
Center Middle Netherlands (IKMN) for their help with data collection, in particular 
drs. C.H.F. Gimbrere. They also thank the “Aart Huisman Stichting” and the 






1. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn H-J. Meeting highlights: 
international consensus panel on the treatment of primary breast cancer. J Clin Oncol 
2001;19:3817-3827. 
 
2. The steering committee on clinical practice guidelines for the care and treatment of 
breast cancer. Adjuvant systemic therapy for women with node-negative breast cancer. 
Can Med Assoc J 1998;158. 
 
3. Hortobagyi GN. Treatment of breast cancer. New Engl J Med 1998;339:974-984. 
 
4. Baak JPA, van Dop H, Kurver PHJ, Hermans J. The value of morphometry to classic 
prognosticators in breast cancer. Cancer 1985;56:374-382. 
 
5. Baak JPA. Mitosis counting in tumors. Hum Pathol 1990;21:683-685. 
 
6. Jannink I, van Diest PJ, Baak JPA. Comparison of the prognostic value of four methods 
to assess mitotic activity in 186 invasive breast cancer patients: classical and random 
mitotic activity assessments with correction for volume percentage of epithelium. Hum 
Pathol 1995;26:1086-1092. 
 
7. van Diest PJ, Baak JPA, Matze-Cok P. Reproducibility of mitosis counting in 2469 breast 
cancer specimens: results from the multicenter morphometric mammary carcinoma 
project. Hum Pathol 1992;23:603-607. 
 
8. Clayton F. Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal 
breast carcinomas. Mitotic count is the best single predictor. Cancer 1991;68:1309-1317. 
 
9. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of 
histological grade in breast cancer: experience from a large study with long-term follow-
up. Histopathology 1991;19:403-410. 
 
10. Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma. Mitotic figure count, 
S-phase fraction, proliferation cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol 
1995;104:42-49. 
 
11. Manders P, Bult P, Sweep CGJ, Tjan-Heijnen VCG, Beex LVAM. The prognostic value of 
the mitotic activity index in patients with primary breast cancer who were not treated with 
adjuvant systemic therapy. Breast Cancer Res Treatm 2002;77:77-84. 
 
12. Kronqvist P, Kuopio T, Collan Y. Morphometric grading in breast cancer: Thresholds for 
mitotic counts. Hum Pathol 1998;29:1462-1468. 
 
13. Groenendijk RPR, Bult P, Tewarie L, Peer PGM, van der Sluis RF, Ruers TJM, Wobbes 




14. Bergers E, Jannink I, van Diest PI, Cuesta MA, Meyer S, van Mourik JC, Baak JPA. The 
influence of fixation delay on mitotic activity and flow cytometric cell cycle variables. Hum 
Pathol 1997;28:95-100. 
 
15. Tsuda H, Akiyama F, Kurosumi M, Sakamoto G, Yamashiro K, Oyama T, Hasebe T, 
Kameyama K, Hasegawa T, Umemura S, Honma K, Ozawa T, Sasaki K, Morino H, 
Ohsumi S. Evaluation of the interobserver agreement in the number of mitotic figures of 
breast carcinomas as simulation of quality monitoring in the Japan National Surgical 
Adjuvant Study of Breast Cancer (NSAS-BC) protocol. Jpn J Cancer Res 2000;91:451-
457. 
 
16. Barry M, Sinha SK, Leader MB, Kay EW. Poor agreement in recognition of abnormal 
mitoses: requirement for standardized and robust definitions. Histopathology 2001;38:68-
72. 
 
17. O’Leary TJ, Steffes MW. Can you count on the mitotic index? Hum Pathol 1996;27:147-
151. 
 
18. Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in node-negative 
breast cancer. A review of studies with sample size more than 200 and follow-up more 
than 5 years. Ann Surg 2002;235:10-26. 
 
19. Aaltomaa S, Lipponen P, Eskelinen M, et al. Mitotic indexes as prognostic predictors in 
female breast cancer. J Cancer Res Clin Oncol 1992;118:75-81. 
 
20. Thor AD, Liu S, Moore DH, et al. Comparison of mitotic index, in vitro bromodeoxyuridine 
labeling and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 
1999;17:470-477. 
 
21. Clahsen PC, van der Velde CJ, Duval C, et al. The utility of mitotic index, estrogen 
receptor and Ki-67 measurements in the creation of novel prognostic indices for node-
negative breast cancer. Eur J Surg Oncol 1999;25:356-363. 
 
22. Page DL, Gray R, Allred C, Dressler LG, Hatfield AK, Martino S, Robert NJ, Wood WC. 
Prediction of node-negative breast cancer outcome by histologic grading and S-phase 
analysis by flow cytometry. An Eastern Cooperative Oncology Group Study (2192). Am J 
Clin Oncol 2001;24:10-18. 
 
23. Schumacher M, Schmoor C, Sauerbrei W, Schauer A, Ummenhofer L, Gatzemeier W, 
Rauschecker H. The prognostic effect of histological tumor grade in node-negative breast 
cancer patients. Breast Cancer Res Treatm 1993;25:235-245. 
 
24. van Diest PJ, Baak JP. The morphometric prognostic index is the strongest 
prognosticator in premenopausal lymph node-negative and lymph node-positive breast 







A comparison and validation in the Dutch 
setting of Adjuvant! and Numeracy; two web-











Introduction: Adjuvant! and Numeracy, are programs predicting the 10-year 
outcome for patients with early breast cancer treated without adjuvant systemic 
therapy or with various commonly used schemes of adjuvant systemic therapy. 
 
Methods: We have compared the prognostic and predictive estimates made by 
Adjuvant! and Numeracy using the characteristics of a population-based cohort of 
breast cancer patients. Subsequently, we have compared estimated outcomes 
with observed outcome. Finally we have compared the survival benefit from 
adjuvant systemic therapy as predicted by Adjuvant! with the presence or 
absence of an indication according to the 2002 and 2004 Dutch guidelines on 
treatment of primary operable breast cancer. 
 
Results: Baseline 10-year recurrence rates estimated with Adjuvant! and 
Numeracy correlated well, but individual estimates differed up to 20%. Average 
baseline recurrence rate estimates and average estimates of the benefit of 
adjuvant systemic therapy were lower when determined with Numeracy than with 
Adjuvant!. Averages of Adjuvant! outcome estimates significantly associated with 
observed outcome percentages, whereas Numeracy averages did not. The 
predicted benefit from adjuvant chemotherapy was less than 5% for 50% and 
16% of patients with a chemotherapy-indication according to the guidelines from 
2002 and 2004, respectively. The predicted benefit from endocrine therapy was 
less than 5% for 37% and 43% of patients with an indication according to the 
guidelines from 2002 and 2004, respectively. 
 
Conclusion: In our opinion Adjuvant! is the preferred model. Adjuvant! is a 
useful and accurate aid for predicting outcome, and can be used in combination 




Adjuvant systemic therapy improves disease free and overall survival in women 
with early breast cancer, with larger absolute gains for those at greater risk.1-3 
However, adjuvant systemic therapy has side effects and is inconvenient; it is not 
useful for many patients. The question is therefore not whether adjuvant systemic 
therapy is effective, but for which patient categories its usefulness is high enough 
to justify its side effects and inconvenience. It is complex to predict the benefit of 
adjuvant systemic for an individual woman with early breast cancer. It involves 
integration of information about baseline prognosis, efficacy of various treatment 
options, and estimates of competing risk. Estimates of the benefit of 
chemotherapy and hormonal therapy influence a women’s willingness to accept 
these therapies, and minimise opportunities for arbitrary decisions.4-7 Estimates of 
the benefit of adjuvant systemic therapy are understood best when presented with 
data in the absolute survival benefit format.8  
 
Several tools have been developed to make individualised estimates of baseline 
prognosis and absolute survival benefit of adjuvant systemic therapy.5,9-11 Two of 
these tools, Adjuvant! and Numeracy, are freely available, web-based 
programs.9,10 Both programs determine a patient’s baseline risk of recurrence 
and/or death at 10 years without adjuvant therapy, and provide an estimate of the 
absolute benefit associated with various commonly used schemes of adjuvant 
systemic treatment. But, as shown in Table 6.1, the programs do differ. 
 
Since 2002, breast cancer patients in The Netherlands are treated according to 
the guideline “Behandeling van het mammacarcinoom”, initiated by The Dutch 
Institute for Healthcare Improvement (CBO).12,13 This guideline was revised in 
2004, and is available through oncoline [www.oncoline.nl], or the CBO-website 
[www.cbo.nl].14 One of the major starting points of the CBO-guidelines is that 
adjuvant systemic therapy for early breast cancer can be considered standard
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Table 6.1. Summary of characteristics of the programs Adjuvant! and Numeracy. 
 
 Adjuvant! Numeracy 
   




Eligible breast cancer 
patients 
 
Unilateral, unicentric, invasive 
adenocarcinoma, adequate 
local treatment, and no 
evidence of distant 
metastasis, T4 features, 
inflammatory breast cancer, 
or of mated or fixed axillary 
nodes 
 
Adequate local treatment, 
tumours graded II or III 
 
 









Estimation of risk reduction 
by adjuvant therapy 
 
EBCTCG data, and data from 
individual randomised trials 
 
 
EBCTCG data, and data from 
individual randomised trials 
 
Baseline factors requested 
 
Age, tumour size, axillary 
lymph node status, co 
morbidity, tumour grade, 
oestrogen receptor status 
 
 
Age, tumour size, axillary 
lymph node status, hormone 
receptor status 
 
End-points of the program 
 
10-year disease free survival, 
overall survival, breast cancer 
related mortality, non-breast 




10-year disease free interval. 
 
Adjuvant therapies which 
effectiveness is estimated 
 
Tamoxifen, anastrozole, or 
ovarian ablation and/or a 
number of chemotherapy 
regimens which are 
considered equally effective 
as CMF, or 10%, 20% or 35% 
more effective than CMF 
Tamoxifen alone, tamoxifen 
and AC, tamoxifen and AC 
and paclitaxel (every 3 
weeks), tamoxifen and AC 
and paclitaxel (dose dense) 
 
 
EBCTCG: Early Breast Cancer Trialists’ Collaborative Group; AC: doxorubicin, cyclophosphamide; CMF: 
cyclophosphamide, methotrexate, fluorouracil. 
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therapy under the condition that it increases the absolute 10-year survival with 5% 
or more. This 5% benefit is assumed for each treatment modality. 
 
In the present study we have compared the prognostic and predictive estimates 
made by Adjuvant! and Numeracy. Subsequently, we have compared estimated 
outcomes with observed outcome. Finally we have validated Adjuvant! for use in 







Between October 1989 and March 1993, consecutive female patients diagnosed 
with operable breast cancer, were asked to participate in an observational study 
on prognostic factors. Patients were recruited in 5 hospitals affiliated with the 
Comprehensive Cancer Centre Middle Netherlands (IKMN). A total of 463 
patients with stage I to III breast cancer gave their written informed consent. Of 
these 456 were treated with either modified radical mastectomy or breast 
conserving therapy, including axillary lymph node dissection. In the inclusion-
period of this study in the entire IKMN-region in total 2165 women had surgery for 
stage I to III breast cancer. The T-stage and N-stage of the 456 study patients 
when compared to the other IKMN-registered patients did not differ significantly. 
The study patients were slightly younger: median age 58 vs. 60 years.  
 
Within the scope of this observational study the prognostic factors required for the 
programs Adjuvant! and Numeracy were prospectively registered. In all study 
patients we also prospectively registered whether adjuvant chemotherapy and/or 
tamoxifen was administered. Adjuvant chemotherapy consisted of 6 cycles of 
cyclophosphamide, methotrexate and fluorouracil (CMF), or 4 cycles of 
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doxorubicin, cyclophosphamide (AC). CMF and AC were considered equally 
effective. Tamoxifen was prescribed once daily, 20 to 40 mg for 2 to 5 years. 
Patients were followed until December 2002, with a median follow-up period of 
10.3 years.  
 
Numeracy requires the hormone-receptor status for the estimation of the benefit 
of adjuvant systemic therapy. The oestrogen-receptor status was determined in 
434 of the 456 patients (95%). Therefore, the comparisons between Adjuvant! 
and Numeracy were performed on these 434 patients. The subsequent analyses 
validating Adjuvant! for use in the Dutch setting used the characteristics from all 
456 patients.  
 
Comparisons between Adjuvant! and Numeracy 
 
Of each patient the prognostic and predictive characteristics required were 
entered in both Adjuvant! (Version 6.0) and Numeracy. Adjuvant! requires 
information on the general health status of the patient. Since we did not register 
comorbidity data, we used the default comorbidity assumption of the program: 
“Minor health problems”. Adjuvant! provides a number of survival end-points 
(Table 6.1). Numeracy provides only one survival end-point, which is called 
"chance of being alive without recurrent cancer", i.e. disease free survival (DFS). 
However, in the estimation of baseline prognosis the program does not account 
for age or comorbidity, and in the estimation of 10-year event-free survival with 
adjuvant therapy Numeracy treats non-breast cancer related mortality as a 
competing cause of death.10 Non-breast cancer related mortality is low in young 
patients, but in the studied cohort only 31% of patients were aged 50 years or 
less. Therefore, we have interpreted the survival end-point estimated by 
Numeracy as the chance of being without recurrent cancer, i.e. disease free 
interval (DFI). Numeracy was updated in September 2003. In this update 
histological grade was added to the baseline factors. Patients with grade I 
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infiltrative ductal cancer were excluded from the Numeracy model as they were 
expected to have a better prognosis than the majority of patients with grade II and 
III cancers. In the cohort of 434 patients grade was determined in 314 (72%) 
patients, 225 patients had a grade II or III tumour. We have compared Adjuvant! 
and Numeracy both using characteristics of these 225 patients and of all 434 
patients. The correlation between the recurrence rates estimated by Adjuvant! 
and Numeracy was determined with Pearson correlation coefficient and linear 
regression analyses. The agreement was determined with Bland-Altman plots.15 
 
Subsequently, observed 10-year DFI was determined with the Kaplan-Meier 
method, for both all 434 patients and clinically relevant subgroups. In these 
analyses disease recurrence was defined as either locoregional recurrence, 
distant metastasis, or contralateral breast cancer. For the same groups, the 
average Adjuvant! and Numeracy estimated values were calculated. Numeracy 
DFI estimates of patients treated with adjuvant chemotherapy only were made by 
using data from the original report by Loprinzi et al.10 In the comparisons between 
observed percentage and average estimated value we assumed the latter 
constant. Therefore, the difference between observed percentage and average 
estimated value was considered significant when it exceeded 1.96 times the 
standard error of the observed percentage. Average Adjuvant! and Numeracy 
estimated DFI values of the entire cohort and the subgroups were mutually 
compared with the two-sided paired-samples t-test. 
 
Validation of Adjuvant! for use in the Dutch setting 
 
The two major outcome figures estimated by Adjuvant! are 10-year DFS and 
overall survival (OS). Average Adjuvant! estimated values of 10-year DFS and OS 
were calculated for all 456 patients and for clinically relevant subgroups. For the 
same groups observed 10-year DFS and OS were determined with the Kaplan-
Meier method. In these analyses DFS was defined as the time between primary 
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surgery and death, locoregional recurrence, distant metastasis, or contralateral 
breast cancer whichever came first. OS was defined as the time between primary 
surgery and death. The difference between observed percentage and average 
estimated value was considered significant when it exceeded 1.96 times the 
standard error of the observed percentage. 
 
 
Figure 6.1. Correlation and linear regression analysis between baseline recurrence rates estimated 
by Adjuvant! and Numeracy, for tumours with histological grade I (o), grade II (▲), grade III (+) and 
with an unknown histological grade (◊). 
 
 












r 2  0.84 
p < 0.001 
Slope         0.97 (0.93 - 1.01) 
Y-intercept -2.2 (-3.8 - -0.5) 

































Besides, 9 equally sized subgroups with a rising 10-year OS were formed. The 
first subgroup contained the 50 patients with the worst prognosis, the ninth 
subgroup the 56 patients with the best prognosis. The association between 
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observed and average Adjuvant! calculated 10-year OS of these 9 groups was 
compared with the perfect association (observed and calculated 10-year OS are 
equal) using linear regression analysis. In the same way 9 subgroups with a rising 
10-year DFS were formed and analysed. 
 
 
Figure 6.2. Agreement, average difference with 95% confidence interval, between baseline 
recurrence rates estimated by Adjuvant! and Numeracy, for tumours with histological grade I (o), 
grade II (▲), grade III (+) and with an unknown histological grade (◊). 
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Finally, using the characteristics of each patient, a comparison was made 
between the presence or absence of an indication for adjuvant chemo- or 
endocrine therapy according to the 2002 and 2004 CBO-guidelines and the by 
Adjuvant! estimated absolute benefit in survival with the adjuvant chemo- or 
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endocrine therapy regimens advised in these guidelines. Both guidelines give no 
standard advice concerning adjuvant chemotherapy for patients aged 70 years or 
more with an ER negative tumour. In the present study, in accordance with 
common practice, all patients aged 70 years or more were classified with a 
negative advice for adjuvant chemotherapy. 
 
A major revision in the 2004 guideline is the advise to use, instead of AC or CMF, 
a more effective chemotherapy regimen comprising 5 cycles of fluorouracil, 
epirubicin, cyclophosphamide (FEC), or in certain cases 6 cycles of docetaxel, 
doxorubicin, cyclophosphamide (TAC). Treatment with TAC is advised for 
premenopausal women with a HER2/neu receptor over expressing tumour and 
positive axillary lymph nodes. The HER2/neu receptor was not determined in the 
patients included in the present study. As a consequence it is not known which 
patients would have been considered for treatment with TAC. Adjuvant! values 
FEC to be 20% more effective than CMF. In the comparison between the 
presence or absence of an indication for adjuvant chemotherapy according to the 
2004 guideline and the calculated benefit of chemotherapy according to Adjuvant! 
for each patient the absolute benefit in 10-year OS was calculated with the 





Comparison between Adjuvant! and Numeracy 
 
Baseline 10-year recurrence rates estimated by Adjuvant! and Numeracy 
correlated well (Figure 6.1). The Pearson correlation coefficient r2 was 0.84 
analysing the entire cohort, and 0.85 analysing grade II or III tumours only. But 
individual recurrence rate estimates could differ up to 20%, the average baseline 
recurrence rate was 3.3% (95% C.I. –12.7 - 19.3%) higher estimated with 
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Figure 6.3. Agreement, average difference with 95% confidence interval, between recurrence rates 
estimated with Adjuvant! and Numeracy using the prognostic and predictive characteristics of 434 
patients, for treatment with adjuvant tamoxifen (A), or adjuvant tamoxifen and doxorubicin / 
cyclophosphamide (B). And agreement between reductions in recurrence rate estimated with 
Adjuvant! and Numeracy for treatment with adjuvant tamoxifen (C), or adjuvant tamoxifen and 
doxorubicin / cyclophosphamide (D). 
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Adjuvant! than with Numeracy (Figure 6.2). Divided into subgroups according to 
histological grade, average Adjuvant! estimated baseline recurrence rates were 
2.3% (95% C.I. -12.6 - 17.2%) lower for grade I tumours, and 3.4% (95% C.I. -
10.7 – 17.5%), 11.1% (95% C.I. –1.2 – 23.4%), 2.9 (95% C.I. –11.3 – 17.1%) 
higher for grade II, grade III, and unknown grade tumours, respectively. 
 
With adjuvant systemic therapy average Numeracy recurrence rate estimates 
were slightly higher than average Adjuvant! recurrence rate estimates (Figure 
6.3): 0.0% (95% C.I.: -15.3 – 15.3%) with adjuvant tamoxifen, 0.8% (95% C.I.: -
12.2 – 13.9%) with adjuvant tamoxifen combined with AC, and 2.9% (95% C.I.: -
10.4 – 16.1%) with adjuvant tamoxifen combined with AC and paclitaxel. 
Estimates of the benefit of adjuvant systemic therapy were lower with Numeracy 
than with Adjuvant! (Figure 6.2). Estimated with Numeracy, the average absolute 
benefit of adjuvant tamoxifen was 3.3% (95% C.I.: -2.9 – 9.5%) lower, the 
average absolute benefit of tamoxifen combined with AC was 4.1% (95% C.I.: -
3.2 – 11.5%) lower, and the average absolute benefit of tamoxifen combined with 
AC and paclitaxel was 6.2% (95% C.I.: -4.6 – 16.9%) lower. Similar results were 
found when the analyses were restricted to the 225 patients with a grade II or III 
tumour: Correlated with Adjuvant!, the average absolute benefit of adjuvant 
tamoxifen, tamoxifen combined with AC, and tamoxifen combined with AC and 
paclitaxel estimated with Numeracy was 3.6% (95% C.I.: -2.7 – 9.9%), 4.9% (95% 
C.I.: -2.2 – 12.0%), and 7.1% (95% C.I.: -3.3 – 17.5%) lower, respectively. 
 
 
Comparison with observed outcomes 
 
In Table 6.2 average estimated DFI values determined with Adjuvant! and 
Numeracy are compared with observed outcome percentages. The average 
Numeracy outcome estimates were 3.6% higher than the average Adjuvant! DFI 
estimates. In subgroup analyses average Numeracy survival estimates were also 
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Table 6.2. Patient-, tumour-, and treatment characteristics with observed and estimated 10-year 
disease free interval.  
 





patients  Obs (SE) Adj! Num 
Total 434  65 (2.5)   68    71 *† 
Age (year)      
≤ 50 134  56 (4.5)   65 †    73 *† 
51 – 60 199  67 (3.5)   68    73 * 
> 70 101  72 (5.2)   70    69 
ER-status      
Negative 104  66 (4.9)   63    72 * 
Positive 330  64 (2.8)   69    71 *† 
Histological grade      
I 89  76 (4.9)   80    80 
II / III 225  63 (3.4)   66    72 *† 
Unknown 120  60 (4.8)   62    64 * 
Tumour size (cm)      
≤ 2.0 267  69 (3.0)   75 †    78 *† 
> 2.0 167  58 (4.1)   56    61 * 
Axillary lymph nodes      
Negative 261  70 (3.0)   76    84 *† 
Positive 173  62 (4.2)   56    53 *† 
Adjuvant systemic therapy      
No 244  67 (3.2)   74    82 *† 
Yes 190  61 (3.8)   60    58 * 
 
Obs: Observed 10-year event rate, Adj!: 10-year event rate estimated by Adjuvant!, Num: 10-year event rate 
estimated by Numeracy, SE: standard error, ER: oestrogen receptor. * significant difference between average 
disease free interval (p<0.05) estimated by Adjuvant! and by Numeracy; † significant difference with observed 




higher, except for the subgroups of patients aged more than 70 years, and 
patients with grade I tumours (not significant), and for patients treated with 
adjuvant systemic therapy (significantly lower). Average Numeracy DFI estimates  
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Table 6.3. Patient-, tumour-, and treatment characteristics with observed and estimated 10-year 








Disease free survival 
(%) 




patients  Obs. (SE) 
Absolute 
difference 
Adj! - Obs. Obs. (SE) 
Absolute 
difference 
Adj! - Obs. 
       
       
Total 456  68.0 (2.3) +1.9 55.5 (2.4) +1.9 
Age (year)       
≤ 50 163  70.5 (3.7) +6.4 57.6 (4.0) +5.8 
51 – 60 97  78.8 (4.2) -1.4 66.1 (4.9) -1.9 
61 – 70 102  69.4 (4.8) +1.6 53.5 (5.1) +4.5 
> 70 94  48.1 (5.8) +0.7 41.8 (5.6) -2.4 
ER-status       
Negative 104  64.8 (4.9) +1.2 55.9 (5.0) +0.4 
Positive 330  68.5 (2.7) +2.2 55.3 (2.8) +2.1 
Unknown 22  78.9 (9.6) -2.1 61.0 (10.8) +2.3 
Histological grade       
I 93  84.2 (3.9) -1.5 66.3 (5.1) +3.3 
II 162  64.1 (4.0) +7.4 52.9 (4.1) +5.4 
III 73  62.6 (5.9) +0.1 50.7 (6.0) -0.7 
Unknown 128  64.1 (4.4) -1.5 53.8 (4.6) -2.3 
Tumour size (cm)       
0,1 – 1,0 80  74.8 (5.0) +6.8 66.3 (5.4) +3.1 
1,1 – 2,0 204  76.1 (3.1) -0.3 58.0 (3.6) +5.1 
2,1 – 3,0 103  57.0 (5.3) +2.7 51.8 (5.2) -4.5 
> 3,0 69  51.8 (6.2) +2.4 41.7 (6.1) +0.2 
Positive lymph nodes      
0 275  75.6 (2.7) +2.2 61.2 (3.1) +2.2 
1 – 3 120  63.5 (4.5) +2.0 53.3 (4.7) +1.1 
> 3 61  43.4 (6.6) -0.7 34.6 (6.2) -2.8 
Tamoxifen       
No 319  74.0 (2.6) +1.7 59.1 (2.9) +2.8 
Yes 137  54.0 (4.5) +2.4 47.2 (4.4) -0.2 
Chemotherapy       
No 384  68.3 (2.5) +2.0 55.3 (2.6) +2.3 
Yes 72  66.1 (5.7) +1.5 56.4 (5.9) +0.3 
       
 
Obs: Observed 10-year event rate, Adj!: 10-year event rate estimated by Adjuvant!, SE: standard error, ER: 
oestrogen receptor. 
 105
were significantly higher than observed DFI percentages for the entire cohort 
(p<0.01), for patients aged 50 years of less (p<0.001), with an oestrogen-receptor 
positive tumour (p=0.01), with a grade II or III tumour (p<0.01), with a tumour 2.0 
cm or less in diameter (p<0.01), without positive axillary lymph nodes (p<0.001), 
and not treated with adjuvant systemic therapy (p<0.001). Numeracy 
underestimated DFI for patients with positive axillary lymph nodes (p=0.04). 
Average Adjuvant! DFI estimates corresponded well with observed DFI 
percentages, but were significantly higher for patients aged 50 years or less 
(p=0.04), and for patients with a tumour 2.0 cm or less in diameter (p=0.04). 
Average Adjuvant! estimated values of 10-year DFS and OS, calculated for all 
456 patients and for clinically relevant subgroups, were not significantly different 
from observed 10-year DFS and OS (Table 6.3). Adjuvant! predicted 10-year OS 
well, but 10-year DFS was underestimated by Adjuvant! when the DFS was low 
and overestimated when the DFS was high (p<0.05 for slope) (Figure 6.4). 
 
Validation of Adjuvant! for use in the Dutch setting 
 
75 of 149 (50%) patients with tumour characteristics adjudging them an indication 
for adjuvant chemotherapy according to the 2002 CBO-guideline, had less than 
5% benefit in 10-year OS from this therapy according to Adjuvant! (Table 6.4). For 
62 of 89 (70%) patients with an ER-positive tumour and an indication for adjuvant 
chemotherapy Adjuvant! estimated less than 5% benefit in 10-year OS, as 
compared with 10 of 53 (19%) patients with an ER-negative tumour and an 
indication for adjuvant chemotherapy. According to Adjuvant! all 35 patients aged 
50 years or more with an ER-positive tumour, and an indication for adjuvant 
chemotherapy according to the 2002 CBO-guideline had less than 5% benefit in 
10-year OS from this therapy. 
 
23 of 173 (16%) patients with tumour characteristics adjudging them an indication 
for adjuvant chemotherapy according to the 2004 CBO-guideline, had less than  
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Figure 6.4. Observed overall survival (A) and disease free survival (B) with standard error of 9 
subgroups with an according to Adjuvant! increasing prognosis. Determined (dotted line) and 
perfect (solid line) linear associations are not significantly different for overall survival, but are 
significantly different for disease free survival. 
 













Slope 0.90 (95% CI 0.75-1.05)





























Slope 0.75 (95% CI 0.52-0.97)
Y-intercept 12.8 (95% CI -0.6-26.3)





















5% benefit in 10-year OS from this therapy according to Adjuvant! (Table 6.5). For 
24 of 110 (22%) patients with an ER-positive tumour and an indication for 
adjuvant chemotherapy Adjuvant! estimated less than 5% benefit in 10-year OS, 
as compared with 1 of 56 (2%) patients with an ER-negative tumour and an 
indication for adjuvant chemotherapy. For 11 patients with positive axillary lymph 
nodes, and an indication for adjuvant chemotherapy Adjuvant! estimated less 
than 5% benefit in 10-year OS from this therapy. The remaining prognostic 
features in these patients were favourable (≤ 2 cm, histological grade I-II, ER-
positive, ≤ 3 positive lymph nodes). For 31 patients with positive axillary lymph 
nodes and a negative indication for adjuvant chemotherapy Adjuvant! estimated 
5% or more benefit in 10-year OS. 23 of these 31 patients were aged 70 years or 
more. 
 
17 patients – with a grade II tumour, 2.1 to 3.0 cm in diameter, and without 
positive axillary lymph nodes – had a negative indication for adjuvant endocrine 
therapy according to the 2002 CBO-guideline, but a positive indication according 
to the 2004 CBO-guideline (Table 6.4 and 6.5). For none of these patients 
Adjuvant! estimated 5% or more benefit in 10-year OS from endocrine therapy 
(average 4.2%). 59 patients without positive axillary lymph nodes were aged 70 
years or more. Of these 11 had a positive indication for adjuvant endocrine 
therapy. For none of these 11 patients Adjuvant! estimated 5% or more benefit in 





In this study we have compared two computer-based programs that predict 10-
year breast cancer outcomes with and without adjuvant systemic therapy: 
Adjuvant! and Numeracy. Adjuvant! determines its estimates of baseline 
prognosis based on data from the Surveillance, Epidemiology, and End Results 
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Table 6.4. 10-year overall survival benefit with adjuvant systemic therapy estimated with Adjuvant! 
subdivided after indication for this treatment according to the 2002 CBO-guideline. 
 
Estimated benefit in 10-year overall survival 
6xCMF / 4xAC Tamoxifen 
Indication adjuvant 
systemic therapy 
according to the 
2002 CBO-guideline 
n < 5% n ≥ 5% avg. n < 5% n ≥ 5% avg. 
        
N0 No 224 4 1.0% 222 0 1.0% 
 Yes 24 13 4.3% 25 8 4.0% 
 Insuff. data 10 0 2.2% 20 0 2.6% 
        
N+ No 68 0 1.7% 40 0 0.0% 
 Yes 51 61 5.4% 36 97 5.7% 
 Insuff. data 1 0 1.9% 4 4 4.3% 
 
CMF: cyclophosphamide, methotrexate, fluorouracil; AC: doxorubicin, cyclophosphamide; n < 5%: number of 
patients with less than 5% benefit in overall survival; n ≥ 5%: number of patients with 5% or more benefit in 
overall survival; N0: no regional lymph node metastases; N+: regional lymph node metastases; avg.: average; 




 (SEER) registry,9 whereas Numeracy’s baseline prognostic estimates are based 
on oncology experts’ predictions.10 Baseline disease recurrence risk estimates 
made by the two programs correlated well, but individual estimates of baseline 
disease recurrence risk differed up to 20%. Baseline outcome estimates 
determined by Numeracy were, on average, higher. Although baseline outcome 
estimates provided by Numeracy were interpreted as DFI estimates, instead of 
DFS estimates as named by the program, Numeracy’s outcome estimates were 
still significantly higher than both Adjuvant!’s DFI estimates, and most observed  
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Table 6.5. 10-year overall survival benefit with adjuvant systemic therapy estimated with 
Adjuvant! subdivided after indication for this treatment according to the 2004 CBO-guideline. 
 
Estimated benefit in 10-year overall survival 
5xFEC / 6xTAC  Tamoxifen / AI 
Indication adjuvant 
systemic therapy 
according to the 
2004 CBO-guideline 
n < 5% n ≥ 5% avg.  n < 5% n ≥ 5% avg. 
         
N0 No 204 8 1.9%  204 0 0.8% 
 Yes 16 35 7.1%  42 8 4.0% 
 Insuff. data 9 3 4.0%  21 0 2.6% 
         
N+ No 27 31 5.2%  40 0 0.0% 
 Yes 11 111 9.5%  36 97 5.7% 
 Insuff. data 0 1 5.1%  4 4 4.3% 
 
FEC: fluorouracil, epirubicin, cyclophosphamide; TAC: docetaxel, doxorubicin, cyclophosphamide; AI: aromatase 
inhibitor; n < 5%: number of patients with less than 5% benefit in overall survival; n ≥ 5%: number of patients with 
5% or more benefit in overall survival; N0: no regional lymph node metastases; N+: regional lymph node 




10-year DFI percentages. The average outcome estimates determined by 
Adjuvant! were close to most observed outcome percentages. The Adjuvant!-
program has recently been validated in a large, prospective, population-based 
study.16 According to that study Adjuvant!’s estimates of prognosis are reliable, 
but overestimate both OS and DFS in women younger than age 35 years, and 
DFS in premenopausal women. Our finding that Adjuvant! overestimated 
prognosis for the subgroup of patients aged 50 years or less is in line with this 
observation. 
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Information regarding the benefit of adjuvant systemic therapy is most easily 
understood when presented as absolute survival benefit.8 Both Adjuvant! and 
Numeracy use the relative risk reduction data from the 1998 EBCTCG overviews 
to predict the absolute risk reductions of adjuvant systemic therapy,1,2 but results 
are different. Compared with Numeracy, Adjuvant! predicted an average absolute 
3.3 – 6.2% larger risk reduction of adjuvant systemic therapy. DFI, DFS and OS 
predicted with Adjuvant! closely matched the respective observed outcomes for 
patients treated with and without adjuvant systemic therapy. These results are in 
accordance with data from the validation study.16 The average Numeracy 
predicted DFI was significantly higher than the average Adjuvant! predicted DFI 
and the observed DFI for patients treated without adjuvant systemic therapy, but 
were significantly lower than the average Adjuvant! predicted DFI and matched 
with the observed DFI for patients treated with adjuvant systemic therapy. These 
findings suggest that Numeracy underscores the benefit of adjuvant systemic 
therapy. 
 
However, it is not possible to make a judgement on the reliability of the measure 
of benefit from adjuvant systemic therapy as estimated by Adjuvant!. For this the 
efficacy of the adjuvant systemic therapies is too limited in proportion to size of 
the confidence interval of the observed OS, DFI and DFS in the subgroups 
treated with adjuvant tamoxifen and chemotherapy. A study with much more 
patients is needed. But, such a large study keeps the limitation that it can only 
validate the efficacy of the adjuvant systemic therapy regimens as given 10-years 
before. 
 
In order to make a judgement on estimations made by Adjuvant! of the efficacy of 
adjuvant systemic therapy, the characteristic of the patients in our cohort were 
used to determine the measure of benefit Adjuvant! would have estimated if these 
patients were treated with the therapies recommended in the 2002 and 2004 
CBO-guidelines. ER-positive patients, and in particular ER-positive patients aged 
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50 years or more, had, if treated with chemotherapy according to the 2002 
guideline and to a lesser extent if treated with chemotherapy according to the 
2004 guideline, according to Adjuvant! a relatively low estimated benefit from this 
therapy. Adjuvant! values the efficacy of adjuvant chemotherapy relatively lower 
in older, and in ER-positive patients. The CBO-guidelines also discern a lower 
efficacy of chemotherapy for women aged 50 years or more, and in particular 
women with an ER-positive tumour, but take no account of this when indicating 
women 50 to 60 years of age.12-14 The guidelines start from an average 25% 
relative reduction in mortality with adjuvant chemotherapy. However, the relative 
reduction in mortality with adjuvant AC or CMF for patients aged 50-69 years with 
an ER-positive tumour is only 10%.2 Both Adjuvant! and the CBO-guidelines base 
their estimations of the absolute survival benefit with adjuvant tamoxifen on the 
1998 EBCTCG meta-analyses.1 The CBO-guidelines start for ER-positive patients 
from a 6% absolute benefit in 10-year OS with tamoxifen for patients without, and 
11% for patients with positive axillary lymph nodes. But, in the cohort studied the 
average 10-year absolute OS benefit with adjuvant tamoxifen was only 4% for 
ER-positive patients without, and 5.7% for ER-positive patients with positive 
axillary lymph nodes. Apparently the prognosis of the patients in the cohort 
studied was better than the prognosis the guidelines used to base their 
indications for adjuvant endocrine therapy on. 
 
In summary, 10-year DFI estimates determined by Adjuvant! and Numeracy 
correlate well, both for patients who are, and who are not treated with adjuvant 
systemic therapy. However, there is no good agreement between the two 
methods. Compared with both Adjuvant! estimates and observed outcome, 
Numeracy estimates of baseline prognosis are too high, and Numeracy estimates 
of absolute risk reduction of adjuvant systemic therapy are too low. Adjuvant! 
estimates of outcome correspond closely to observed outcome. In our opinion 
Adjuvant! is the preferred prognostic model. Adjuvant! appears an accurate aid for 
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predicting the risk of mortality and disease recurrence in patients with early breast 
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Acute toxicity of concurrent adjuvant 
radiotherapy and chemotherapy (CMF or AC) in 
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Background: The concurrent administration of adjuvant chemotherapy and 
radiotherapy in breast cancer treatment might lead to an increased incidence of 
side effects.  
 
Methods: In this prospective, non-randomised, comparative study the acute 
toxicity of radiotherapy alone (RT) and radiotherapy concurrent with doxorubicin-
cyclophosphamide (AC/RT) and radiotherapy concurrent with cyclophosphamide-
methotrexate-5-fluorouracil (CMF/RT) was compared. We used the Common 
Toxicity Criteria (CTC) to score the level of acute toxicity before, during and 6 
months after the completion of the period of irradiation. The number of hospital 
admissions as well as the compliance of chemotherapy, were noted.  
 
Results: We observed that patients treated with AC/RT and CMF/RT had 
significant higher incidences of (high-grade) skin-toxicity, oesophagitis, dyspnoea, 
malaise, anorexia, nausea and hospital admission compared with those treated 
with RT only. The target-volume of radiotherapy was the main predictor of (high-
grade) acute skin toxicity and oesophagitis. AC/RT was associated with 
significant more (high-grade) skin toxicity than CMF/RT. The dose of 
chemotherapy was reduced to less than 85% of the planned dose in 11% of 
patients, 17% of patients treated with concurrent chemotherapy and radiotherapy 
needed admission to hospital . 
 
Conclusions: From the results of our study, we conclude that the concurrent 
administration of adjuvant chemotherapy and radiotherapy leads to an 




The optimal sequence of radiotherapy and adjuvant chemotherapy in breast 
cancer patients is not clearly defined. The delivery of both regimens can be 
planned sequentially (chemotherapy administered before or after radiotherapy), 
concurrently (chemotherapy and radiotherapy given simultaneously), or 
alternating (radiotherapy administered in the midst of the chemotherapy courses, 
commonly referred to as “sandwich” therapy). 
 
In order to limit the side-effects experienced, most centres deliver radiotherapy 
and adjuvant chemotherapy sequentially. However, a delay in the delivery of 
radiotherapy1-5 or systemic therapy6 might have a negative effect on treatment 
outcome. In an evaluation of data from a number of trials from the National 
Surgical Adjuvant Breast and Bowel Project (NSABP), in which concurrent 
treatment was compared with sequential treatment, concurrent treatment was 
associated with a decreased incidence of ipsilateral breast recurrences after 
breast conserving therapy (BCT).7 However, it is known that the concurrent 
administration of radiotherapy and chemotherapy leads to an increased incidence 
of side effects,8-15 that the chemotherapy regimens used in these NSABP trials 
are considered substandard today and that the degree of toxicity of combined 
chemotherapy and radiotherapy also depends on the type of cytotoxic drugs 
used.16,17 The increased level of toxicity, caused by the concurrent administration 
of chemo- and radiotherapy, might compromise optimal dose delivery, with 
respect to both radiotherapy and chemotherapy treatments.15,18 This might have 
negative influence on treatment outcome. Hence, the balance between gain in 
disease control versus the side-effects might be different with the current 
chemotherapy and radiotherapy regimens. 
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In this prospective, comparative, non-randomised study, the acute toxicity of 
radiotherapy concurrent with cyclophosphamide-methotrexate-fluorouracil 
(CMF/RT) was compared with that of radiotherapy concurrent with  
(epi-)doxorubicin-cyclophosphamide (AC/RT). A third group treated with 
radiotherapy only (RT) was added. 
 
 
Table 7.1. Patient-, tumour- and treatment-characteristics. 
 AC/RT CMF/RT RT
Number of patients 61 51 42
  
Median age in years (range) 47 (27-64) 43 (28-56) 53 (37-
74)
  
Interval between date of surgery and 
start of radiotherapy in days (range) 
57 (35-119) 58 (31-103) 53 (31-
98)
  
Interval between date of surgery and 
start of chemotherapy in days 
(range) 
35 (15-91) 29 (9-92) 
  
Primary surgical treatment  
Breast conserving therapy 34 (56%) 37 (73%) 36 (86%)
Modified radical mastectomy 27 (44%) 14 (27%) 6 (14%)
  
Tumour size    
≤ 20 mm 18 (30%) 25 (49%) 28 (67%)
21 – 50 mm 36 (59%) 24 (47%) 13 (31%)
> 50 mm 7 (11%) 2 (4%) 1 (2%)
  
Axillary lymph node status  
Tumour negative 4 (7%) 3 (6%) 27 (64%)
Tumour positive 57 (93%) 48 (94%) 15 (36%)
  
Target-volume radiation therapy  
Local 25 (41%) 28 (55%) 30 (71%)
Loco-regional 36 (59%) 23 (45%) 12 (29%)
 
AC, doxorubicin-cyclophosphamide; CMF, cyclophosphamide-methotrexate-fluorouracil; RT, radiotherapy. 
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Between January 1996 and August 1999, all eligible patients referred to the 
department of radiotherapy at the University Medical Centre Utrecht (UMC 
Utrecht) were asked to participate in this prospective, comparative study. 
Informed consent was obtained from 154 patients. Patients were eligible if they 
were referred for RT or chemotherapy (CT)/RT, both after BCT and modified 
radical mastectomy (MRM). 112 patients received CT/RT; 61 patients were 
treated with AC/RT and 51 with CMF/RT. 42 patients treated with RT only were 
studied as controls. The choice between AC and CMF was made by the treating 
medical oncologist and was based on personal preference. Table 8.1 depicts the 
patient and treatment characteristics for the 3 patient groups. The AC/RT and 
CMF/RT groups were not fully balanced, specifically with respect to tumour and 
treatment characteristics . However, these differences were not statistically 
significant (P>0.05). The differences in patient-, tumour- and treatment 
characteristics between the CT/RT and RT groups can be explained by the 
treatment protocols used. In premenopausal patients, chemotherapy was given in 
the presence of axillary lymph node metastases. Since patients in the CT/RT 
groups were mostly premenopausal, we preferably included patients less than 50 
years of age in the RT group. As a consequence, most patients included in the 
RT only group were axillary lymph node-negative. The higher rate of patients 
treated with BCT and local radiotherapy in the RT group can be explained by the 
fact that local radiotherapy is part of BCT. Radiation therapy of the breast 
(including a boost dose) was an integral part of the BCT. Patients treated with 
MRM were referred for radiotherapy based on characteristics of either the primary 
tumour and/or the axillary lymph node status. In these patients, adjuvant systemic 





Radiation therapy was administered at the Department of Radiotherapy at the 
UMC Utrecht. After lumpectomy and axillary dissection, radiotherapy (whole 
breast irradiation (WBI) and a boost dose) was indicated. Thoracic wall irradiation 
(TWI) after MRM was administered when resection margins were found to be 
tumour-positive or when skin involvement was assessed by the pathologist. 
Regional radiotherapy encompassing the axillary, infraclavicular, supraclavicular 
and parasternal lymph node areas, was added in the presence of 4 or more 
positive axillary lymph node metastases; tumour involvement of the apical axillary 
lymph node; extranodal tumour growth; or when skin involvement was assessed 
by the pathologist. WBI, as well as TWI, were administered using opposed 
tangential photon fields on a 6 or 10 MV linear accelerator to a dose of 50 Gy at 2 
Gy per fraction. In case of WBI, a boost dose of 14-16 Gy (tumour free resection 
margins) or 20 Gy (focally tumour positive resection margins) was given using 
either photon wedge fields or electrons. The dose was specified at the isocentre, 
according to the guidelines of the International Commision on Radiation Units and 
Measurements (ICRU) report 50.19 In all cases of TWI, tissue equivalent material 
was applied on the skin to ensure a 100% skin dose. The thoracic wall, as well as 
the axillary, infraclavicular, supraclavicular and parasternal lymph node areas 
were treated using a technique described earlier.20 A dose of 50 Gy was given. 
With regard to the parasternal field, an anterior-posterior field was given. Thirteen 
fractions were administered with photons (encompassing the oesophagus) and 12 
fractions with electrons. In 2 patients, who required regional radiotherapy, it was 
possible to include the parasternal lymph node chain within the breast tangential 
fields. 7 patients who were referred for local radiotherapy after breast-conserving 
tumorectomy participated in the European Organization for Research and 
Treatment of Cancer (EORTC) 10925/22922 trial (parasternal/medial 
supraclavicular radiotherapy versus none) and were treated with a parasternal 
field and a medial supraclavicular field in addition to their breast tangential fields. 
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The median interval between the date of surgery and the start of radiotherapy 
was 56 days (range 31-119 days). No difference in duration of the duration of 




During the accrual period of this study (1996-1999), the medical oncologists had 
their own preference with regard to prescribing either AC or CMF as adjuvant 
systemic treatment. However, a change was observed over the years. In 1996, 
two thirds of the patients who required chemotherapy received CMF, whilst in 
1998 two thirds received AC. The drugs were administered according to the 
following doses and schedules: AC: doxorubicin - 60 mg per square meter of 
body-surface area intravenously (i.v.) on day 1; cyclophosphamide - 600 mg per 
square meter i.v. on day 1; cycles were repeated every 21 days for a total of four 
cycles. CMF: cyclophosphamide - 100 mg per square meter orally for 14 days, 
starting on day 1; methotrexate – 40 mg per square meter i.v. on days 1 and 8; 5-
fluorouracil – 600 mg per square meter i.v. on days 1 and 8; cycles were repeated 
every 28 days for a total of six cycles. Depending on the level of haematological 
toxicity (leucocytes <3.0x109, granulocytes <1.5x109 or thrombocytes <50x109), 
the medical oncologist decided to reduce chemotherapy doses or expel 
deliverance. The median interval between the date of surgery and start of 
chemotherapy was 35 days (range 15-91 days) for AC/RT patients and 29 days 
(range 9-92 days) for CMF/RT patients. Five percent of AC/RT patients received 
the first cycle of chemotherapy during radiotherapy, 49% received one cycle 
before start of radiotherapy, 39% two cycles and 7% three cycles. Eight percent 
of CMF/RT patients received their first cycle of chemotherapy during 
radiotherapy, 47% received one cycle before start of radiotherapy, 41% two 
cycles and 4% three cycles. Planned and delivered chemotherapy doses were 
calculated in mg per meter squared per week. Dose reduction was calculated by 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































Toxicity parameters were scored using the Common Toxicity Criteria (CTC) as 
developed by the National Cancer Institute (NCI).21 In the present study toxicity 
parameters were prospectively scored by the treating radiation oncologist before 
the start of radiotherapy, every two weeks during radiotherapy, and 3 weeks, 6 
weeks, 3 months and 6 months after the completion of radiotherapy. Items scored 
were the level of skin-toxicity, the severity of symptoms like oesophagitis/ 
dysphagia, cough, dyspnoea, malaise, anorexia, nausea, vomiting, and fever 
(Table 8.2). When cough was scored as grade 2 or 3, or when dyspnoea was 
scored as grade 3 or 4, or in case of other pulmonary complaints, a chest X-ray 
was taken in order to evaluate the presence or absence of radiation pneumonitis. 
When skin toxicity grade 4 was scored, the desquamated skin surface area was 
measured in square centimetres. The maximum surface area of skin 
desquamation was noted. For all of the toxicity parameters, the maximum toxicity 
grade was taken. For all of the toxicity parameters, except for skin, toxicity grade 
2 or higher was considered clinically relevant and therefore high-grade. For skin 
toxicity grade 3 or higher was considered clinically relevant and therefore defined 
as high-grade. The number of hospital admissions that took place during the 
follow-up period was registered. Dose reductions of chemotherapy to less than 




Statistical analysis was carried out using the Statistical Package for the Social 
Sciences (SPSS) for Windows, release 9.0 (SPSS Inc.). Incidences of high-grade 
maximum toxicity were compared in univariate analyses using the Pearson Chi-
square test. Incidences of high-grade toxicity (significant in univariate analysis), 
hospital admissions and clinically relevant dose reductions of chemotherapy were 
compared in logistic regression analysis. Independent variables included in the  
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Table 7.3. Incidences of maximum common toxicity criteria grade 2, 3 and 4 during follow-up. 
Toxicity AC/RT CMF/RT CT/RT RT
Number of patients 61 51 112 42  
Skin §   ‡
Grade 2 15 (25%) 20 (39%)  35 (31%) 22 (52%)  
Grade 3 0 (0%) 3 (6%)  3 (3%) 2 (5%)  
Grade 4 43 (70%) 21 (41%)  64 (57%) 9 (21%)  
Esophagitis / dysphagia §  †
Grade 2 14 (23%) 7 (14%)  21 (19%) 2 (5%)  
Grade 3 8 (13%) 0 (0%)  8 (7%) 0 (0%)  
Grade 4 0 (0%) 2 (4%)  2 (2%) 0 (0%)  
Cough    
Grade 2 7 (11%) 4 (8%)  11 (10%) 2 (5%)  
Grade 3 0 (0%) 0 (0%)  0 (0%) 0 (0%)  
Grade 4 0 (0%) 0 (0%)  0 (0%) 0 (0%)  
Dyspnea   †
Grade 2 23 (38%) 18 (35%)  41 (37%) 5 (12%)  
Grade 3 3 (5%) 3 (6%)  6 (5%) 2 (5%)  
Grade 4 0 (0%) 1 (2%)  1 (1%) 0 (0%)  
Radiation pneumonitis    
Grade 2 3 (5%) 2 (4%)  5 (4%) 1 (2%)  
Grade 3 0 (0%) 0 (0%)  0 (0%) 0 (0%)  
Grade 4 0 (0%) 0 (0%)  0 (0%) 0 (0%)  
Malaise   ‡
Grade 2 38 (62%) 31 (61%)  69 (62%) 17 (40%)  
Grade 3 15 (25%) 6 (12%)  21 (19%) 2 (5%)  
Grade 4 0 (0%) 0 (0%)  0 (0%) 0 (0%)  
Anorexia §  ‡
Grade 2 25 (41%) 10 (20%)  35 (31%) 1 (2%)  
Grade 3 6 (10%) 5 (10%)  11 (10%) 1 (2%)  
Grade 4 0 (0%) 0 (0%)  0 (0%) 0 (0%)  
Nausea §  †
Grade 2 15 (25%) 6 (12%)  21 (19%) 1 (2%)  
Grade 3 3 (5%) 1 (2%)  4 (4%) 0 (0%)  
Grade 4 0 (0%) 0 (0%)  0 (0%) 0 (0%)  
Vomiting   §
Grade 2 8 (13%) 4 (8%)  12 (11%) 0 (0%)  
Grade 3 1 (2%) 0 (0%)  1 (1%) 0 (0%)  
Grade 4 0 (0%) 0 (0%)  0 (0%) 0 (0%)  
Fever   §
Grade 2 7 (11%) 5 (10%)  12 (11%) 0 (0%)  
Grade 3 0 (0%) 0 (0%)  0 (0%) 0 (0%)  
Grade 4 0 (0%) 0 (0%)  0 (0%) 0 (0%)  
 
AC, doxorubicin-cyclophosphamide; CMF, cyclophosphamide-methotrexate-fluorouracil; CT, chemotherapy; RT, 
radiotherapy. Incidences of maximum high-grade toxicities compared in bivariate analyses. § P<0.05; † P<0.01; ‡ 
P<0.001. 
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analysis were age, primary surgical therapy (MRM vs. BCT), target-volume of 
radiotherapy (local radiotherapy vs. loco-regional radiotherapy) and 
chemotherapy regimen (CT/RT vs. RT and CMF/RT vs. AC/RT). Since WBI was 
delivered after BCT only and TWI after MRM only, MRM vs. BCT could - in cases 
of acute skin toxicity - also be interpreted as TWI vs. WBI. T-stage or N-stage 
were not considered to be confounding factors, and we therefore decided not to 
include these variables in the multivariate analyses. The influence of the 
independent variables mentioned above on the duration of skin toxicity, 
oesophagitis/dysphagia and malaise was determined using Cox regression 
analysis. Their effect on the natural logarithm of the maximum area of skin 





Incidences of maximum toxicity grades 2, 3 and 4 are presented in Table 8.3. 
Significantly more patients receiving CT/RT than patients receiving RT only 
experienced severe skin toxicity (60% vs. 26%), and moderate or severe 
esophagitis / dysphagia (28% vs. 5%), dyspnoea (43% vs. 17%), malaise (81% 
vs. 45%) anorexia (41% vs. 4%), nausea (22% vs. 2%), vomiting (12% vs. 0%) 
and fever (11% vs. 0%). When patients receiving AC/RT were compared with 
those receiving CMF/RT more high-grade skin-toxicity (70% vs. 47%) and 
moderate to high-grade toxicity of the oesophagus (36% vs. 18%) was observed 
for the AC/RT group. The intake of food was also significantly decreased (30% vs. 
14%), and more patients experienced moderate to high (Grades 2 and 3) 
anorexia (51% vs. 29%). 
 
The three study groups (AC/RT, CMF/RT and RT) were not fully  balanced with 
respect to other potential risk factors for acute toxicity such as primary surgical 
treatment, radiotherapy regimen and age (Table 1). Hence, a logistic regression 
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Table 7.4. Multiple logistic regression analysis on incidences of high-grade toxicities. 
 




















































Age and type of primary surgical treatment were not significantly associated with the end-points and are therefore 
not shown. 
n.s, not significant; O.R., odds ratio; 95% C.I., 95% confidence interval; CT, chemotherapy, RT, radiotherapy; AC, 
doxorubicin-cyclophosphamide; CMF, cyclophosphamide-methotrexate-fluorouracil; MRM, modified radical 




analysis was performed. The results are given in Table 8.4. The administration of 
CT/RT, compared with RT, was associated with significantly more high-grade skin 
toxicity, oesophagitis/dysphagia, dyspnoea, malaise, anorexia and nausea. After 
adjustment for the other potential risk factors, when the AC/RT group was 
compared with the CMF/RT group, a borderline significance was noted 
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specifically with respect to more high-grade skin toxicity (P=0.05, odds ratio (OR) 
2.4). There was also a trend towards more high-grade oesophagitis/dysphagia, 
anorexia and nausea in patients receiving AC/RT compared with patients 
receiving CMF/RT (p=0.06-0.08, OR 2.1-2.6) (Table 8.4). The inclusion of 
regional lymph node areas in the radiotherapy regimen was associated with 
significantly more high-grade skin-toxicity and oesophagitis/dysphagia. The type 




Figure 7.1. The effect of radiotherapy on the geometric mean of desquamated skin surface area in 
patients treated with concurrent radio- and adjuvant chemotherapy, 2 weeks, 4 weeks and 6 weeks 
after start of radiotherapy, and 3 weeks, 6 weeks, 3 months and 6 months after completion of 
radiotherapy. Geometric means of areas of desquamated surface are presented together with 
number of patients involved. 
 









































The administration of CT/RT was, after adjustment for the other potential risk 
factors, associated with significantly more hospital admissions. During the follow-
up, 19 of 112 patients (17%) treated with CT/RT were (in total 30 times) admitted 
to hospital with acute complications of treatment. Only 1 patient (2%) treated with 
RT only was admitted to hospital. The median duration of hospital admissions 
was 11 days (range 2-64 days). More than half of the hospital admissions was 
related to local toxicity in the irradiated area. A dose reduction of chemotherapy to 
less than 85% of the planned dose was necessary in 12 patients (11%) and was 
independent of treatment regimen, tumour and patient characteristics. 
 
The duration of high-grade skin toxicity was significantly longer after TWI (median 
34 days) than after WBI (median 22 days) (p=0.02). The geometric mean value of 
surface areas of skin desquamation was higher after TWI than that after WBI 
(Figure 8.1). After WBI 41 patients (38%) developed high-grade skin toxicity for a 
median period of 22 days (range 14 – 92 days). After TWI 37 patients (79%) 
developed high-grade skin toxicity for a median of 34 days (range 14 –221 days). 
Six weeks after the completion of radiotherapy, 19 patients had not recovered 
from high-grade skin toxicity. All 19 patients had received concurrent 
chemotherapy and radiotherapy on the regional lymph nodes (including WBI or 
TWI). Six months after completion of radiotherapy 3 patients still had high-grade 
skin toxicity. The incidence of high-grade toxicity of the oesophagus was 
significantly higher in patients treated with loco-regional radiotherapy compared 
with that in patients treated with local radiotherapy (Figure 8.2), but the duration of 
complaints did not differ significantly. 33 patients developed high-grade 
oesophagitis/dysphagia for a median duration of 16 days (range 9 – 217 days). 
109 patients developed high-grade malaise for a median duration of 64 days 
(range 13 – 224 days). The duration of high-grade skin toxicity, 
oesophagitis/dysphagia and malaise, and the maximum surface area of skin 
desquamation, was not associated with the type of chemotherapy. 
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Figure 7.2. The effect of concurrent chemotherapy and local and loco-regional radiotherapy on the 
prevalence of high-grade oesophagitis/dysphagia 2 weeks, 4 weeks and 6 weeks after start of 
radiotherapy, and 3 weeks, 6 weeks, 3 months and 6 months after completion of radiotherapy. 
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For breast cancer patients, the optimal sequence of radiotherapy and adjuvant 
chemotherapy is not clearly defined. Theoretically, one can expect the largest 
treatment benefit when both modalities are given concurrently.7 However, it has 
been reported that the concurrent administration of the two modalities leads to an 
increased incidence of side effects.8 In retrospective studies on the combination 
of chemotherapy and radiotherapy the following results were reported: a 
worsened cosmetic outcome after breast conserving therapy;9,10 an increased 
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level of haematological toxicity;11 an increased incidence of severe skin 
toxicity;12,15 a higher incidence of radiation pneumonitis11,14 and arm oedema.13 
Moreover it has been reported that an increased level of toxicity compromises an 
optimal dose delivery, with respect to both radiotherapy and chemotherapy.15,18 In 
some retrospective studies, however, no or only a minor increase in toxicity has 
been found when chemotherapy and radiotherapy were given concurrently.13,18,22 
 
The enhancement of side effects of radiation by chemotherapy does not only 
depend on the sequencing of radiotherapy and chemotherapy, but also on the 
type of cytotoxic drugs used. Skin effects are more frequently reported with the 
use of doxorubicin and 5-Fluorouracil.17 Others found that doxorubicin in 
particular potentiated the effect of radiotherapy on the skin and the normal 
mucosa of the oesophagus.16 In the present study, we prospectively compared 
the acute toxicity of two commonly used adjuvant chemotherapy regimens (CMF 
and AC) administered concurrently with radiotherapy. A third group treated with 
radiotherapy only was added. 
 
Others have already stated that although conservative surgery combined with 
breast irradiation is associated with low incidences of significant (late) 
complications, both cosmetic result en the risk of complications can be 
unfavourably influenced by the addition of nodal irradiation and/or chemotherapy.8 
In the present study, the addition of adjuvant chemotherapy, concurrent with 
radiotherapy, did increase the risk of acute toxicity. CT/RT, AC/RT more than 
CMF/RT, caused a higher incidence of high-grade skin toxicity than RT alone. 
However, the inclusion of regional nodal areas in the irradiation field was of 
greater importance. As shown in Table 8.5, almost 90% of patients treated with 
concurrent AC and loco-regional radiotherapy developed high-grade skin toxicity 
compared with 44% of patients treated with concurrent AC and local radiotherapy. 
TWI was the main predictor of duration of high-grade skin toxicity and of the 
extent of desquamated skin surface. This could be explained by the fact that, in 
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cases of TWI, tissue equivalent material was applied on the skin to ensure a 
100% skin dose. In contrast, during WBI (as part of radiotherapy during BCT), no 
tissue equivalent material was used, resulting in a lower skin dose of 
approximately 75%. In our multivariate analysis, TWI was not significantly related 
to the incidence of high-grade skin toxicity. 
 
Loco-regional radiotherapy (encompassing the oesophagus) and the addition of 
concurrent chemotherapy to radiotherapy were the most important risk factors for 
developing high-grade oesophagitis/dysphagia. There was a trend towards more 
high-grade oesophagitis/dysphagia when AC/RT was administered instead of 
CMF/RT. As shown in Table 8.5, more than half of all patients treated with loco-
regional radiotherapy concurrent with AC developed high-grade 
oesophagitis/dysphagia, compared with only 12% of patients treated with local 
radiotherapy (and hence no irradiation of the oesophagus) concurrent with AC.  
 
In the present study, symptomatic radiation pneumonitis was observed in only a 
small proportion of patients. Grade 2 pneumonitis (requiring steroid treatment) 
was seen in 2% of patients treated with RT and in 4% of patients treated with 
CT/RT. Because of these low incidences of pneumonitis, it was not possible to 
draw any further conclusions. Lingos and colleagues retrospectively reviewed 
1624 breast cancer patients for the risk of developing radiation pneumonitis.14 
They concluded, in line with our observations, that radiation pneumonitis following 
conservative surgery and radiation therapy for breast cancer is a rare 
complication, but that it was more likely to occur in patients treated with both loco-
regional radiotherapy and chemotherapy (particularly when given concurrently 
with radiation therapy). Others found similar results.13 In the present study, the 
administration of chemotherapy concurrently with radiotherapy did cause 
significant more dyspnoea on exertion. But only 5% of patients (in all three 
groups) experienced dyspnoea at normal levels of activity, and only one patient 
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experienced dyspnoea at rest. We found no difference in incidence of lung toxicity 
between CMF/RT and AC/RT. 
 
 
Table 7.5. Acute toxicity, hospital admissions and chemotherapy dose reduction according to 
radiotherapy- and chemotherapy regimen. 
 
 
Local radiotherapy Loco-regional  Radiotherapy 
 RT CMF/RT AC/RT RT CMF/RT AC/RT
       
High-grade skin toxicity 20% 25% 44% 42% 74% 89% 
High-grade skin toxicity six 
weeks after completion of 
radiotherapy 
0% 0% 0% 0% 30% 36% 
High-grade 
oesophagitis/dysphagia  
3% 7% 12% 8% 30% 53% 
Hospital admissions 3% 11% 8% 0% 22% 25% 
Chemotherapy dose reduction 
(< 85%) 
 7% 4%  17% 14% 
 




The administration of chemotherapy was the sole risk factor for developing high-
grade malaise, anorexia, nausea, vomiting and fever. There was a trend towards 
more high-grade anorexia and nausea in the group of patients receiving AC/RT 
compared with the group of patients receiving CMF/RT. In the RT group high-
grade malaise, anorexia, nausea, vomiting and fever hardly developed. In the 
chemotherapy groups, nausea, vomiting and fever were mainly limited to grade 2 
(moderate) toxicity level. 
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As shown in table 8.5, the risk of acquiring a complication necessitating hospital 
admittance was higher during or after a concurrent chemotherapy and loco-
regional radiotherapy regimen than after than after local RT. More than 20% of 
patients treated with concurrent loco-regional radiotherapy and chemotherapy 
compared with approximately 10% of patients treated with concurrent local 
radiotherapy and chemotherapy and 3% of patients treated with radiotherapy 
alone were admitted to hospital. In addition, more patients received an 
inadequate dose of chemotherapy when chemotherapy was combined with 
concurrent loco-regional radiotherapy. When chemotherapy was combined with 
local radiotherapy approximately 5% of patients received an inadequate dose, 
compared with approximately 15% of patients when chemotherapy was combined 
with loco-regional radiotherapy (Table 8.5). Denham and colleagues also found a 
trend towards a lower mean delivered fraction of planned dose of chemotherapy 
while extending the radiation field.18 Dubey and colleagues studied the delivery of 
CMF concurrent with a reduced, local radiotherapy regimen. Seven percent of 
patients received inadequate drug doses.15  
 
We conclude that in the treatment of patients with early breast cancer, the 
administration of adjuvant chemotherapy concurrently with loco-regional 
radiotherapy is too toxic. In particular, more skin desquamation and moderate to 
severe oesophagitis/dysphagia can be anticipated. In addition, more than 20% of 
patients need to be admitted to hospital with acute complications of therapy, and 
approximately 15% of patients receive less than 85% of the planned dose of 
chemotherapy. The concurrent administration of local radiotherapy to the breast 
and chemotherapy is less toxic. However, the administration of local radiotherapy 
concurrent with AC still leads to high-grade skin toxicity in 44% of patients. As 
anthracyclin-containing regimens, in particular 4 courses of AC, are considered 
standard for adjuvant chemotherapy in early breast cancer in many countries, the 
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In this chapter the results and conclusions from the studies presented in the 




Advances in adjuvant therapy 
 
Chapter 1 showed that in the past decade the breast cancer related mortality in 
The Netherlands decreased despite an increasing incidence. The decrease in 
mortality has been partly attributed to the enhanced use as well as the increased 
efficacy of adjuvant systemic therapy. Starting the 1980s, an increasing number 
of patients were treated with adjuvant systemic therapy. It is expected that the 
decrease in mortality will continue in the forthcoming years.1 
 
Since the 1980s, new and more effective adjuvant therapy options and strategies 
have emerged, and are emerging. Cyclophosphamide, methotrexate, fluorouracil 
(CMF) has been replaced by anthracyclin containing regimens which are about 
20% more effective.2 Two years of tamoxifen has been replaced by 5 years of 
tamoxifen, and adjuvant chemotherapy and endocrine therapy are often 
combined, with an additive efficacy.2 A recent trial shows that in patients with 
axillary node positive (ANP) breast cancer treatment with docetaxel, doxorubicin, 
cyclophosphamide (TAC), as compared to fluorouracil, doxorubicin, 
cyclophosphamide (FAC), results in a 28% reduction in the risk of disease 
recurrence, being the primary endpoint of this study.3 The ATAC-trial shows that 
in postmenopausal patients with hormone receptor positive tumours adjuvant 
treatment with anastrozole, as compared to tamoxifen, reduces the incidence of 
the primary endpoint, disease recurrence rate, by about 13%.4 Trastuzumab is a 
monoclonal antibody directed against the HER2/neu receptor. Recent trials with 
this new adjuvant therapy option, presented at the 2005 meeting of the American 
Society of Clinical Oncology (ASCO), show that the adjuvant administration of 
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trastuzumab reduces the disease recurrence rate in patients over expressing the 
HER2/neu receptor by about 50%.5 
 
It is striking that almost all recent trials on adjuvant therapy in early breast cancer 
use disease recurrence, instead of “the gold standard” overall survival, as their 
primary study endpoint. It has been argued that the absence of recurrent disease 
is the best indicator of the efficacy of the anti-tumour strategy.6 However, what is 
the primary goal of adjuvant systemic therapy: a reduction in disease recurrence, 
or a reduction in mortality? As shown in Chapter 3, a decrease of breast cancer 
recurrences is not automatically followed by a better overall survival. Besides, the 
definition of breast cancer recurrence varies between trials, and usually contains 
events that are not directly related to mortality, such as locoregional relapse and 
contralateral breast cancer. Non-disease related mortality is also often included in 
the definition of disease recurrence, but is not influenced by the adjuvant 
regimens regularly used.2 Chapter 3 shows that the inclusion of contralateral 
breast cancer and/or non-disease related death in the definition of outcome 
substantially influences estimates of breast cancer recurrence rate and survival, 
specifically in elder patients and patients with a good prognosis. Clear definitions 
of endpoints and competing events are therefore crucial for the interpretation and 
comparison of outcome studies, and should be provided in all clinical trials. It is 
my opinion that overall survival should be the primary study endpoint in trials that 
study the efficacy of adjuvant treatment options in elderly (e.g. postmenopausal) 
patients and in patients with a relative good prognosis (e.g. axillary node negative 
breast cancer). 
 
Chapter 3 also studied the measure of bias generated by the Kaplan-Meier 
approach due to informative censoring of contralateral breast cancer or non-
disease related death. The Kaplan-Meier method requires non-informative 
censoring, which means that those individuals who are censored should be as 
likely to have the subsequent event of interest as those who remain in the study. 
 141
In particular competing events might cause informative censoring. For this reason 
others have propagated an approach that accounts for informative censoring in 
survival analyses in the presence of competing events. In Chapter 3 minor 
differences were observed between estimated outcome determined by the 
Kaplan-Meier method and a competing risk method. However, differences 
became more substantial when relative more patients were censored due to 
competing events. Nevertheless, in most follow-up studies on patients with early 





The evolvements in the adjuvant systemic therapy of early breast cancer have 
complicated decisions on whom to treat, and with what type of adjuvant systemic 
therapy. Information on baseline prognosis, i.e. without adjuvant systemic 
therapy, and on the efficacy of adjuvant systemic therapy regimens, as provided 
by randomised clinical trials and meta-analyses, has become indispensable for 
these decisions. 
 
The major prognostic variables that are used in clinical practice still are the 
number of (tumour) positive axillary lymph nodes and tumour size. But, as shown 
in Chapter 2, a number of other variables, such as in this study histological 
grade, mitotic counts (MC), cathepsin D, urokinase plasminogen activator (UPA) 
and it’s inhibitor type 1 (PAI-1), are associated with disease recurrence and 
survival as well. In particular UPA and PAI-1 appeared to be strong prognostic 
variables. The prognostic value of UPA and PAI-1 has also been shown in a large 
prospective clinical trial,7 and a pooled meta-analysis.8 In my opinion the clinical 
value of UPA and PAI-1 is undervalued. As it appears that the major drawback for 
broad use in clinical practise of UPA and PAI-1 is a lack in standardisation with 
respect to immunoassays used, methods of tumour extraction and protein 
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determination, a large prospective multicentre study on the reproducibility, 
attainability and clinical relevance of UPA and PAI-1 is warranted. 
 
In Chapter 4 the prognostic value of oestrogen receptor (ER) and progesterone 
receptor (PR), as determined both by immunocytochemical assay (ICA) and by 
enzyme immuno assay (EIA) was prospectively evaluated. The agreement 
between EIA and ICA was moderate to substantial (Kappa 0,58 and 0,65 
respectively for ER and PR). No differences in prognostic value of hormone 
receptors detected by ICA or EIA were found. Both ER and PR proved to be weak 
prognostic factors. But, of course, the main purpose to determine hormone 
receptors is their ability to predict the efficacy of endocrine therapy. Although ER 
was identified more than 30 years ago, still much needs to be learned. There is 
convincing evidence that ER operates in a complex interacting network that 
ensures the viability of the cancer cells.9 Resistance to tamoxifen is linked to 
overexpression of HER2/neu, and aromatase inhibitors show particular benefit in 
ER postive, PR negative patients.9,10 It has been shown that ER positive tumours 
are genetically distinct from ER negative tumours.11 ER negative and ER positive 
breast cancer should be considered different diseases, requiring not only different 
treatment strategies, but probably also different panels of variables for 
determination of prognosis. It has to be studied which way of assessing the ER 
status of a breast tumour (ICA, EIA, or on gene level) is best when ER is used in 
this light. 
 
The prognostic value of MC in axillary node negative breast cancer is still a matter 
of debate. As shown in Chapter 5, the determination of MC is an inexpensive, 
fast and reproducible way of assessing proliferation in routine practice. But, in the 
study presented in Chapter 5 no significant association between MC and disease 
recurrence and survival was found, which eventually could be explained by the 
favourable tumour characteristics of  this group of patients and the associated low 
number of events. Based on data in the literature a positive association between 
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MC and survival in axillary node negative breast cancer may exist, but in Chapter 
5 the extent of this putative association and its clinical relevance is argued. 
Others, however, are certain that the prognostic value of MC holds for 
premenopausal patients with axillary lymph node negative disease, and state that 
MC should be used in clinical practice.12 Just recently the results from the 
multicentre morphometric mammary carcinoma project (MMMCP) were 
published. In this study the absolute difference in 10 year disease specific survival 
between ANN breast cancer patients with low and high MC was 22% (92% vs. 
70%) (HR 4.42, 95% C.I. 2.79 – 7.01).13 These results are far better than those 
reported in the past by other investigational groups. 
 
New techniques for the study of potential prognostic variables are rapidly 
developing at both the gene and protein level.14 Two of these techniques, reverse 
transcriptase polymerase chain reaction (RT-PCR) and DNA sequencing 
(microarray techniques) allow the simultaneous analysis of the expression of a 
large number of genes in a single experiment. Paik et al. identified 21 genes that 
can be detected by RT-PCR analysis and used them to group breast cancer 
patients into risk categories with distant recurrence rates at 10 years of 6.8% and 
30.5%.15 Van ‘t Veer et al. and van de Vijver et al. used microarray analysis and 
grouped patients according to a 70-gene expression profile into categories with 
94.5% and 54.6% survival rates at 10 years.16,17 These results are promising, but 
not substantially better than those achievable with classical variables.18 In 
Chapter 2 of this thesis a prognostic index was created using tumour size, 
number of postive axillary lymph nodes and PAI-1. 29% of patients were in the 
good prognosis group with a 10-year disease specific survival of 95% and a 10-
year disease free interval of 85%. The clinical relevance of both the 21-gene RT-
PCR and the 70-gene expression profile will soon be tested and compared with 
the classical methods of prognostication in large multicentre clinical trials. The 21-
gene RT-PCR will be tested in the PACCT (Program for the Assessment of 
Clinical Cancer Tests) trial, the 70-gene expression profile in the MINDACT 
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(Microarray for Node Negative Disease may Avoid Chemotherapy) trial. These 
trials are indispensable to establish the clinical value of the genomic techniques. 
The prognostic value of genomic tests will probably increase when they are 
combined with classical prognosticators, such as tumour size or axillary lymph 
node status. At this moment the 70-gene expression profile and the 21-gene RT-
PCR, though commercially available, should not be used outside the setting of a 
clinical trial, yet. 
 
 
Computer programs used for treatment decision-making 
 
Several tools have been developed to make individualised estimates of baseline 
prognosis and absolute survival benefit of adjuvant systemic therapy. Two of 
these tools, Adjuvant! and Numeracy, are freely available, web-based 
programs.19,20 Both programs determine a patient’s baseline risk of recurrence 
and/or death at 10 years without adjuvant therapy, and provide an estimate of the 
absolute benefit associated with various commonly used schemes of adjuvant 
systemic treatment. As shown in Chapter 6, 10-year disease free interval 
estimates determined by Adjuvant! and Numeracy correlate well. However, there 
is no good agreement between the estimates made by the two programs. 
Compared with both Adjuvant! estimates and observed outcome, Numeracy 
estimates of baseline prognosis are too high, and Numeracy estimates of 
absolute risk reduction of adjuvant systemic therapy are too low. Estimates of 
recurrence free survival and overall survival made by Adjuvant! are accurate, 
when compared with observed outcome. Therefore, Adjuvant! is the preferred 
prognostic model. The data presented in Chapter 6 concerning the reliability of 
Adjuvant! are in line with the results from a recently published, large, prospective, 
population-based, validation study.21 The Adjuvant! website is regularly updated. 
Currently (July 2005), there are 4 different versions of Adjuvant! for breast cancer 
available on the Adjuvant! website (www.adjuvantonline.com): a standard version 
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6.0 (used in Chapter 6), a standard version 7.0 (the most current version, with 
modest changes about treatment options and efficacy, and prognostic estimates 
for very young patients), a genomic version 7.0 (for patients for whom prognostic 
information from the 21-gene RT-PCR is available), and a version designed for 
decision making for hormone receptor positive postmenopausal patients at the 
time of completing 5 years of adjuvant tamoxifen (using data from the study 
published by Goss et al.).22 It is likely that Adjuvant! will gain in importance in 
clinical practice in the nearby future. In my opinion Adjuvant! should be routinely 
used when informing patients on the pros and cons of adjuvant systemic therapy. 
Adjuvant! should be used by the treating physician to demonstrate the expected 
benefit of both the proposed and alternative adjuvant treatment strategy options. 
However, it should be stressed that the reliability and accuracy of the computer 
program should be validated on a regular basis. 
 
 
Sequence of adjuvant chemotherapy and post-operative 
radiotherapy 
 
The optimal sequence of radiotherapy and adjuvant chemotherapy is not clearly 
defined. Theoretically, one can expect the largest treatment benefit when both 
modalities are given concurrently.23 However, it has been reported that the 
concurrent administration of the two modalities can lead to an increased 
incidence of side effects.24 Chapter 7 showed that the administration of adjuvant 
chemotherapy concurrently with, in particular loco-regional radiotherapy is too 
toxic. More skin desquamation and moderate to severe oesophagitis/dysphagia 
can be anticipated. In addition, more than 20% of patients need to be admitted to 
hospital with acute complications of therapy, and approximately 15% of patients 
receive less than 85% of the planned dose of chemotherapy. The concurrent 
administration of local radiotherapy to the breast and chemotherapy is less toxic. 
But, the administration of local radiotherapy concurrent with AC still leads to high-
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grade skin toxicity in 44% of patients. As anthracyclin-containing regimens have 
become standard for adjuvant chemotherapy in early breast cancer -i.e. FAC, 
FEC, or TAC which are considered more toxic than the regimens studied in 
Chapter 7- the concurrent administration of adjuvant chemotherapy and 
radiotherapy is dissuaded. 
 
If post-operative radiotherapy and adjuvant chemotherapy are not to be given 
concurrently, they have to be administered sequentially. The question that arises 
is which modality should be given first, radiotherapy or chemotherapy. 
Radiotherapy given after completion of adjuvant chemotherapy leads to an 
increased incidence of locoregional recurrences.25 On the other hand, 
postponement of chemotherapy carries the risk of an increased incidence of 
distant metastasis.26 One, small sized (n=244), randomised trial with long-term 
follow-up has been published that compared radiotherapy followed by 
chemotherapy to chemotherapy followed by radiotherapy.27 This trial did not show 
any survival benefit for either sequence. However, the chemotherapy regimen 
provided in this trial is nowadays considered sub optimal. Soon, a large 
multicentre randomised trial will be started in The Netherlands to answer the 
question which modality should be given first. Endpoints of this study will be long-
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In dit hoofdstuk worden de resultaten en conclusies van de studies gepresenteerd 
in de voorgaande hoofdstukken van dit proefschrift samengevat en besproken in 
een breder perspectief. 
 
 
Ontwikkelingen in de aanvullende behandeling van het 
mammacarcinoom 
 
Hoofdstuk 1 liet zien dat in de afgelopen tien jaar de aan mammacarcinoom 
gerelateerde sterfte in Nederland is afgenomen ondanks een toegenomen 
incidentie. De afname in sterfte is ten dele toe te schrijven aan een toename van 
gebruik en effectiviteit van aanvullende systemische therapie. Vanaf de jaren 80 
zijn steeds meer patiënten behandeld met aanvullende systemische therapie. De 
verwachting is dat de daling in sterfte in de komende jaren zal doorzetten.1 
 
Nieuwe, effectievere aanvullende behandelopties en -strategieën zijn sinds de 
jaren ‘80 ontwikkeld, en ontwikkelen zich. Cyclofosfamide, methotrexaat, 
fluorouracil (CMF) is vervangen door anthracycline-bevattende schema's, welke 
zo'n 20% effectiever zijn.2 Twee jaar behandeling met tamoxifen is vervangen 
door 5 jaar en aanvullende chemotherapie en endocriene therapie worden veelal 
gecombineerd met een additief effect.2 Een recente studie bij patiënten met 
okselklier positief mammacarcinoom laat zien dat behandeling met docetaxel, 
doxorubicine, cyclofosfamide (TAC), vergeleken met fluorouracil, doxorubicine, 
cyclofosfamide (FAC), resulteert in een 28% afname van het risico van recidief 
ziekte, het primaire eindpunt van deze studie.3 De ATAC-studie laat bij 
postmenopausale vrouwen met hormoon receptor positief mammacarcinoom zien 
dat aanvullende behandeling met anastrozole, in vergelijking met tamoxifen, de 
kans op het primaire eindpunt van de studie, recidief ziekte, vermindert met 
ongeveer 13%.4 Trastuzumab is een monoklonaal antilichaam gericht tegen de 
HER2/neu receptor. Recente studies met deze nieuwe behandeloptie, 
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gepresenteerd in 2005 op het congres van “the American Society of Clinical 
Oncology” (ASCO), laten zien dat aanvullende behandeling met trastuzumab bij 
patiënten met een tumor met overexpressie van de Her2-receptor de kans op 
recidief ziekte vermindert met zo’n 50%.5 
 
Het is opvallend dat vrijwel alle recente studies naar aanvullende behandeling bij 
het mammacarcinoom recidief ziekte, in plaats van de “gouden standaard” 
overleving, als primair eindpunt gebruiken. Het is beargumenteerd dat het 
ontbreken van recidief ziekte de beste indicator is voor de effectiviteit van een 
antitumor strategie.6 Maar wat is het primaire doel van aanvullende systemische 
behandeling: een vermindering van recidief ziekte of een vermindering van 
sterfte? Hoofdstuk 3 laat zien dat een verschil in mammacarcinoom recidief niet 
automatisch gevolgd wordt door een verschil in overleving. Daarnaast verschilt de 
definitie van mammacarcinoom recidief tussen de studies en bevat deze meestal 
gebeurtenissen die niet direct gerelateerd zijn aan sterfte, zoals locoregionaal 
recidief en contralateraal mammacarcinoom. Niet mammacarcinoom gerelateerde 
sterfte wordt ook vaak opgenomen in de definitie van mammacarcinoom recidief, 
maar wordt niet beïnvloed door de gewoonlijk gebruikte aanvullende 
behandelingen.2 Hoofdstuk 3 laat zien dat het wel of niet opnemen van 
contralateraal mammacarcinoom en/of niet-ziekte gerelateerde sterfte in de 
definitie van uitkomst een substantiële invloed heeft op de schattingen van het 
mammacarcinoom recidiefcijfer en sterftecijfer, met name bij oudere patiënten en 
patiënten met een goede prognose. Heldere definities van eindpunten en 
concurrerende gebeurtenissen zijn daarom cruciaal voor de interpretatie en 
vergelijking van uitkomst studies en zouden gegeven moeten worden in alle 
klinische studies. Naar mijn mening moet overleving het primaire eindpunt zijn in 
studies die aanvullende systemische behandelopties bestuderen in oudere (bijv. 
postmenopausale) patiënten en patiënten met een relatief gunstige prognose 
(bijv. met een okselklier negatief mammacarcinoom). 
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Hoofdstuk 3 bestudeert ook de mate van bias gegenereerd door de Kaplan-
Meier methode ten gevolge van informatieve censurering van contralateraal 
mammacarcinoom en niet-ziekte gerelateerd overlijden. De Kaplan-Meier 
methode vereist niet-informatieve censurering, wat betekent dat de individuen die 
gecensureerd worden een even grote kans hebben op een nog te volgen 
gebeurtenis van interesse als de individuen die in de studie blijven. Met name 
concurrerende gebeurtenissen kunnen informatieve censurering veroorzaken. 
Om deze reden hebben anderen een benadering gepropageerd die in de 
overlevingsanalyses rekening houdt met informatieve censurering in de 
aanwezigheid van concurrerende gebeurtenissen. In de studie beschreven in 
Hoofdstuk 3 werden slechts kleine verschillen geobserveerd tussen uitkomst-
schattingen bepaald met de Kaplan-Meier methode en een methode die rekening 
houdt met concurrerende gebeurtenissen. Wel werden de verschillen groter 
wanneer relatief meer patiënten gecensureerd werden vanwege een 
concurrerende gebeurtenis. Desalniettemin mag verwacht worden dat 
informatieve censurering in de meeste follow-up studies bij patiënten met vroeg 





De ontwikkelingen in de aanvullende systemische behandeling van het 
mammacarcinoom hebben beslissingen omtrent wie te behandelen en met welk 
type aanvullende systemische therapie gecompliceerd. Informatie over basale 
prognose (d.w.z. zonder aanvullende systemische therapie) en effectiviteit van 
aanvullende systemische behandelingen, verkregen uit gerandomiseerde 




De belangrijkste prognostische factoren gebruikt in de klinische praktijk zijn nog 
steeds het aantal aangedane okselklieren en de grootte van de tumor. Maar zoals 
aangetoond in Hoofdstuk 2 zijn vele andere variabelen, zoals in deze studie 
histologische graad, mitose index (MI), cathepsine D, urokinase plasminogeen 
activator (UPA) en zijn remmer type 1 (PAI-1), geassocieerd met recidief ziekte 
en overleving. Met name UPA en PAI-1 blijken sterke prognostische variabelen. 
De prognostische waarde van UPA en PAI-1 is ook aangetoond in een grote 
prospectieve klinische studie7 en in een meta-analyse.8 Naar mijn mening wordt 
de prognostische waarde van UPA en PAI-1 op dit moment onvoldoende 
gewaardeerd. De belangrijkste redenen om UPA en PAI-1 niet in de klinische 
praktijk te gebruiken lijken te zijn een gebrek aan standaardisatie van de 
gebruikte immunoassays en van de methode van tumor extractie en eiwit 
bepaling. Een grote prospectieve studie in meerdere centra naar de 
reproduceerbaarheid, haalbaarheid en klinische relevantie van UPA en PAI-1 is 
daarom gerechtvaardigd. 
 
In Hoofdstuk 4 wordt de prognostische waarde van zowel de oestrogeen 
receptor (ER) als de progesteron receptor (PR), bepaald met een 
immunocytochemische assay (ICA) en een enzym immuno assay (EIA) 
prospectief geëvalueerd. De overeenstemming tussen EIA en ICA was redelijk tot 
substantieel (Kappa respectievelijk 0,58 en 0,65 voor ER en PR). Het maakte 
geen verschil voor de prognostische waarde van de hormoonreceptoren of deze 
bepaald werden met ICA of EIA. Zowel ER als PR bleken zwakke prognostische 
factoren. Maar de belangrijkste reden om de hormoonreceptoren te bepalen is 
uiteraard hun vermogen om de effectiviteit van endocriene therapie te 
voorspellen. De ER is reeds meer dan 30 jaar geleden geïdentificeerd, maar er 
valt nog steeds veel te bestuderen. Inmiddels is er overtuigend bewijs dat de ER 
opereert in een complex interactief netwerk wat de levensvatbaarheid van 
kankercellen moet waarborgen.9 Resistentie tegen tamoxifen is gerelateerd aan 
overexpressie van HER2/neu en aromatase remmers hebben met name een 
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voordeel ten opzichte van tamoxifen bij patiënten met een ER positieve, PR 
negatieve tumor.9,10 Het is aangetoond dat ER positieve tumoren genetisch sterk 
verschillen van ER negatieve tumoren.11 ER negatief en ER positief 
mammacarcinoom moeten als verschillende ziekten beschouwd worden en 
vereisen niet alleen een verschillende behandelstrategie, maar waarschijnlijk ook 
verschillende sets van variabelen om de prognose te bepalen. Het moet nog 
uitgezocht worden welke methode om de ER te bepalen (ICA, EIA, of op gen 
niveau) het beste is, wanneer de ER in dit kader wordt gebruikt. 
 
De prognostische waarde van de MI in okselklier negatief mammacarcinoom is 
nog altijd onderwerp van discussie. Zoals aangetoond in Hoofdstuk 5 is het 
bepalen van de MI een goedkope, snelle en reproduceerbare methode om in de 
dagelijkse praktijk de mate van proliferatie vast te stellen. Maar de studie 
gepresenteerd in Hoofdstuk 5 toont geen significante associatie tussen MI en 
recidief ziekte en overleving aan, wat verklaard wordt door de prognostisch 
gunstige tumorkarakteristieken en het hiermee samenhangende lage aantal als 
eindpunt gedefinieerde gebeurtenissen. Gebaseerd op data uit de literatuur lijkt 
een positieve associatie tussen MI en overleving in okselklier negatief 
mammacarcinoom waarschijnlijk, maar de mate van deze veronderstelde 
associatie en de bijkomende klinische relevantie wordt in Hoofdstuk 5 betwist. 
Anderen zijn er echter van overtuigd dat de MI relevante prognostische waarde 
heeft voor premenopausale patiënten met een okselklier negatief 
mammacarcinoom en stellen dat de MI gebruikt moet worden in de klinische 
praktijk.12 Zeer recent zijn de resultaten van het “multicentre morphometric 
mammary carcinoma project (MMMCP)” gepubliceerd. In deze studie bedroeg het 
absolute verschil in 10 jaars overleving tussen patiënten met een okselklier 
negatief mammacarcinoom met lage en hoge MI 22% (92% vs. 70%) (HR 4.42, 
95% C.I. 2.79 – 7.01).13 Deze resultaten zijn veel beter dan in het verleden 
gerapporteerde resultaten van andere onderzoeksgroepen. 
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In hoog tempo ontwikkelen zich nieuwe technieken voor het bestuderen van 
potentiële prognostische factoren, zowel op gen niveau als op eiwit niveau.14 
Twee van deze technieken, te weten reverse transcriptase polymerase chain 
reaction (RT-PCR) en DNA-sequencing met microarray technologie, maken het 
mogelijk een groot aantal genen gelijktijdig te analyseren in één enkel 
experiment. Paik en anderen identificeerden met behulp van RT-PCR een panel 
van 21 genen, waarmee ze patiënten met mammacarcinoom konden groeperen 
naar de kans op het hebben van een metastase op afstand na 10 jaar van 6,8% 
en 30,5%.15 Van ’t Veer e.a. en van de Vijver e.a. gebruikten microarray 
technologie en groepeerden patiënten met behulp van een 70-genen expressie 
profiel in categorieën met een 94,5% and 54,6% overlevingskans na 10 jaar.16,17 
Deze resultaten zijn veelbelovend, maar niet substantieel beter dan de resultaten 
die te bereiken zijn met klassieke, klinische variabelen.18 In Hoofdstuk 2 van dit 
proefschrift is een prognostische index gecreëerd met gebruikmaking van de 
tumorgrootte, het aantal aangedane okselklieren en de PAI-1 bepaling. 29% van 
de patiënten werden ingedeeld in de groep met een gunstige prognose en 
hadden na 10 jaar een kans op overlijden aan mammacarcinoom van 5%, en op 
recidief ziekte van 15%. De klinische relevantie van zowel het 21-genen RT-PCR 
panel, als het 70-genen expressie profiel zal binnenkort getest en vergeleken 
worden met de klassieke methoden van prognosestelling in grote 
gerandomiseerde klinische studies. Het 21-genen RT-PCR panel zal getest 
worden in de PACCT (Program for Assessment of Clinical Cancer Tests) studie, 
het 70-genen expressie profiel in de MINDACT (Microarray for Node Negative 
Disease may Avoid Chemotherapy) studie. Deze studies zijn essentieel om de 
klinische waarde van de genomische technieken vast te stellen. Waarschijnlijk zal 
de prognostische waarde van genomische testen toenemen wanneer deze 
gecombineerd worden met klassieke prognostische factoren zoals tumor grootte 
en okselklierstatus. Op dit moment zouden het 70-genen expressie profiel en het 
21-genen RT-PCR panel, hoewel commercieel beschikbaar, nog niet gebruikt 
moeten worden buiten studieverband. 
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Computer programma’s te gebruiken bij het maken van 
behandel beslissingen 
 
Er zijn de afgelopen jaren diverse hulpmiddelen ontwikkeld om een 
geïndividualiseerde schatting te maken van basale prognose en absolute winst 
van aanvullende systemische therapie. Twee van deze hulpmiddelen, Adjuvant! 
en Numeracy, zijn gratis programma’s, via internet te gebruiken.19,20 Beide 
programma’s bepalen voor een patiënt haar risico op recidief ziekte en/of 
overlijden na 10 jaar zonder aanvullende therapie en geven een schatting van het 
absolute voordeel geassocieerd met diverse veel gebruikte aanvullende 
systemische therapie schema’s. In Hoofdstuk 6 wordt getoond dat schattingen 
van het 10-jaars recidief ziekte vrije interval gemaakt door Adjuvant! en Numeracy 
een goede correlatie vertonen. Er is echter geen goede overeenstemming tussen 
de schattingen gemaakt door beide programma’s. In vergelijking met zowel 
schattingen gemaakt door Adjuvant! als geobserveerde uitkomsten zijn de door 
Numeracy gemaakte schattingen van de basis-prognose te hoog en die van de 
absolute risico reductie door aanvullende systemische therapie te laag. De door 
Adjuvant! gemaakte schattingen van ziektevrije overleving en overleving zijn 
accuraat wanneer deze vergeleken worden met daadwerkelijk geobserveerde 
uitkomsten. Adjuvant! is daarom het prognostische model van voorkeur. De data 
gepresenteerd in Hoofdstuk 6 betreffende de betrouwbaarheid van Adjuvant! 
komen overeen met de resultaten van een recent gepubliceerde, grote, 
prospectieve, validatie studie.21 De website van Adjuvant! wordt regelmatig 
geactualiseerd. Momenteel (juli 2005) zijn er 4 verschillende versies van 
Adjuvant! for Breast Cancer beschikbaar op de Adjuvant! website 
(www.adjuvantonline.com): Een standaard versie 6.0 (gebruikt in Hoofdstuk 6), 
een standaard versie 7.0 (de meest actuele versie, met kleine veranderingen met 
betrekking tot behandel opties en effectiviteit en prognostische schattingen bij 
zeer jonge vrouwen), een genomics versie 7.0 (voor patiënten waarvan 
prognostische informatie van het 21-genen RT-PCR panel beschikbaar is) en een 
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versie ontworpen voor behandel-beslissingen voor hormoon receptor positieve 
postmenopausale patiënten op het moment dat ze 5 jaar aanvullend met 
tamoxifen behandeld zijn (gebruikmakend van de resultaten van de studie van 
Goss en anderen).22 Het is waarschijnlijk dat Adjuvant! in de nabije toekomst een 
steeds belangrijkere plaats in de klinische praktijk zal innemen. Naar mijn mening 
zou Adjuvant! standaard gebruikt moeten worden wanneer patiënten 
geïnformeerd worden over de voor- en nadelen van aanvullende systemische 
therapie. Adjuvant! zou door de behandelend specialist gebruikt moeten worden 
om de winst in (ziektevrije) overleving door zowel de voorgestelde behandeling 
als door alternatieve behandelopties te demonstreren. Het moet echter benadrukt 
worden dat de betrouwbaarheid en accuraatheid van het computer programma 
met regelmaat gevalideerd zullen moeten worden. 
 
 
De volgorde van aanvullende chemotherapie en post-
operatieve radiotherapie 
 
De optimale volgorde van radiotherapie en aanvullende chemotherapie is 
onduidelijk. Theoretisch kan het grootste behandeleffect verwacht worden 
wanneer beide modaliteiten gelijktijdig gegeven worden.23 Maar het is 
gerapporteerd dat de gelijktijdige toediening van beide modaliteiten kan leiden tot 
een verhoogde incidentie van bijwerkingen.24 Hoofdstuk 7 laat zien dat het 
toedienen van aanvullende chemotherapie gelijktijdig met, met name 
locoregionale radiotherapie, te toxisch is. Meer ontvelling van de huid en 
gemiddeld tot ernstige oesofagitis / dysfagie werden gezien. Bovendien werden 
meer dan 20% van de patiënten opgenomen in het ziekenhuis met acute 
complicaties van de behandeling en ongeveer 15% van de patiënten ontvingen 
minder dan 85% van de geplande dosis chemotherapie. De gelijktijdige 
toediening van lokale radiotherapie op de mamma en chemotherapie is minder 
toxisch. Maar de gelijktijdige toediening van lokale radiotherapie en AC 
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veroorzaakt nog altijd hooggradige huidtoxiciteit bij 44% van de patiënten. 
Aangezien anthracycline bevattende schema’s –te weten FAC, FEC of TAC 
welke als meer toxisch beschouwd worden dan de behandelschema’s gebruikt in 
Hoofdstuk 7- de standaard aanvullende chemotherapeutische behandeling zijn 
geworden, wordt de gelijktijdige toediening van aanvullende chemotherapie en 
radiotherapie afgeraden. 
 
Als postoperatieve radiotherapie en aanvullende chemotherapie niet gelijktijdig 
gegeven kunnen worden, zullen ze na elkaar gegeven moeten worden. De vraag 
is vervolgens welke modaliteit eerst gegeven moet worden, radiotherapie of 
chemotherapie. Als de radiotherapie gegeven wordt na het afronden van de 
aanvullende chemotherapie leidt dit tot een verhoogde incidentie van 
locoregionale recidieven.25 Aan de andere kant draagt uitstel van chemotherapie 
het risico van een verhoogde incidentie van metastasen op afstand.26 Er is één 
kleine (n=244) gerandomiseerde studie gepubliceerd die radiotherapie gevolgd 
door chemotherapie vergelijkt met chemotherapie gevolgd door radiotherapie.27 
Deze studie liet geen verschil in overleving zien tussen de twee armen. Maar het 
chemotherapieschema in deze studie wordt tegenwoordig als suboptimaal 
beschouwd. Binnenkort wordt in Nederland een grote gerandomiseerde studie 
opgestart met als doel de vraag te beantwoorden welke modaliteit eerst gegeven 
moet worden. Eindpunten van deze studie zullen zijn: lange termijn locoregionale 











LIST OF ABBREVIATIONS 
 
AC doxorubicin, cyclophosphamide 
ANN axillary node negative 
ANP axillary node positive 
BCT breast conserving therapy 
BR-grade Bloom-Richardson grade 
CBO Kwaliteitsinstituut voor de gezondheidszorg 
CI confidence interval 
CMF cyclophosphamide, methotrexate, fluorouracil 
CTC Common Toxicity Criteria 
DFI disease free interval 
DFS disease free survival 
DMFS distant metastasis free survival 
DSS disease specific survival 
EBCTCG early breast cancer trialists' collaborative group 
EIA enzyme immuno assay 
ER oestrogen receptor 
FAC fluorouracil, doxorubicin, cyclophosphamide 
FEC fluorouracil, epirubicin, cyclophosphamide 
HR hazard rate 
ICA immunocytochemical assay 
IKMN Comprehensive Cancer Centre Middle Netherlands 
LBA ligand binding assay 
LRRR locoregional recurrence rate 
MC mitotic counts 
MRM modified radical mastectomy 
OS overall survival 
PAI-1 plasminogen activator inhibitor type 1 
PR progesterone receptor 
RT radiotherapy 
RT-PCR reverse transciptase polymerase chain reaction 
TAC docetaxel, doxorubicin, cyclophosphamide 
TWI thoracic wall irradiation 
UPA urokinase plasminogen activator 






Het is zover, mijn boek is af. Maar een proefschrift schrijf je niet alleen. Dit 
proefschrift is dan ook niet compleet zonder een aantal mensen te bedanken.  
 
Alvorens ik namen ga noemen wil ik eerst de vrouwen bedanken die belangeloos 
toestemming hebben gegeven hun gegevens te gebruiken voor de studies in dit 
proefschrift. Voor hen die nog in leven zijn, ik hoop dat het goed met jullie gaat. 
 
Natuurlijk en bovenal gaat mijn dank uit naar de mede-auteurs van de stukken in 
dit proefschrift. Jullie hebben talloze waardevolle uren gestoken in het 
meedenken over, en lezen en bijsturen van de stukken in dit proefschrift. Bij 
tegenslagen wisten jullie me te motiveren om door te gaan en bij nieuwe ideeën 
traden jullie op als klankbord. Buiten hen die plaats hebben genomen in de 
oppositie mogen de namen van Frank Bellot, Robert Chabot, Charles Gimbrère, 
Rene van Helvoirt, Carole Kooijman, Hein Putter, Hans Ruitenberg, Derk Rutgers, 
Ingeborg van der Tweel en de huisartsen in de IKMN-regio hierbij niet onvermeld 
blijven. Zonder jullie hulp en inzet waren de studies in dit proefschrift nooit tot 
stand gekomen. Heel veel dank hiervoor. 
 
Behalve aan de bovengenoemde personen ben ik dank verschuldigd aan de 
mensen in mijn naaste omgeving met wie ik de andere belangrijke(re) dingen in 
het leven deel. Pa, Ma, Werner, schoonfamilie en vrienden bedankt voor de 
getoonde interesse en voor alle liefde, vriendschap en steun. Annemarie Pijlman 
en Paul Hamberg, ik ben zeer vereerd dat jullie mijn paranimfen willen zijn. Lieve 
pa en ma. Jullie onvoorwaardelijke steun de vormt de basis van dit proefschrift. 
Werner en ik mogen in onze handjes knijpen met zulke ouders. Dit proefschrift is 
als dank aan jullie opgedragen.  
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Tenslotte lieve Charlotte, samenleven met mij is niet altijd even makkelijk, en het 
delen van wat mij bezighoudt is niet mijn sterkste punt. Dank voor al je geduld, je 
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Universiteit van Utrecht. In 1993 haalt hij zijn doctoraal examen, gevolgd door het 
artsexamen in januari 1996. Nog diezelfde maand start hij zijn loopbaan als arts-
assistent, in het Bosch Medicentrum, locatie Willem-Alexander Ziekenhuis, te ’s 
Hertogenbosch. Een jaar later wordt de overstap gemaakt naar het 
Diakonessenhuis te Utrecht. Alhier begint hij rond mei 1997 op uitnodiging van dr. 
J.W.R. Nortier, destijds als internist werkzaam in het Diakonessenhuis, aan het 
controleren, aanvullen, corrigeren, en analyseren van de database die de basis 
zou gaan vormen van de meeste hoofdstukken van dit proefschrift. In september 
1999 mag hij aan de opleiding tot internist beginnen. Eerst perifeer in het 
Diakonessenhuis Utrecht (opleider: dr. J.B.L. Hoekstra), vervolgens academisch 
in het Universitair Medisch Centrum Utrecht (opleider: prof. dr. D.W. Erkelens). In 
januari 2004 stapt hij over naar het Leids Universitair Medisch Centrum om 
opgeleid te worden in het aandachtsgebied Medische Oncologie (opleider: prof. 
dr. J.W.R. Nortier). Deze opleiding vindt deels plaats tijdens de opleiding tot 
internist, welke in Leiden wordt afgerond op 31 augustus 2004 (opleider: prof. dr. 
A.E. Meinders). Sinds september 2005 is hij werkzaam als internist-oncoloog in 
het Medisch Centrum Leeuwarden te Leeuwarden. De auteur is in 2003 getrouwd 
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